Avid Bioservices (CDMO) 10-K/A 24 Apr 24 2023 FY Annual report (amended) Financial data

Cover

Cover - USD ($)	12 Months Ended
	Apr. 30, 2023	Jun. 09, 2023	Oct. 31, 2022
Cover [Abstract]
Document Type	10-K/A
Amendment Flag	true
Amendment Description	restated financials
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Apr. 30, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--04-30
Entity File Number	001-32839
Entity Registrant Name	AVID BIOSERVICES, INC.
Entity Central Index Key	0000704562
Entity Tax Identification Number	95-3698422
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	14191 Myford Road
Entity Address, City or Town	Tustin
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92780
City Area Code	(714)
Local Phone Number	508-6100
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	CDMO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 887,300,000
Entity Common Stock, Shares Outstanding		62,729,154
Documents Incorporated by Reference [Text Block]	Part III of this report incorporates certain information by reference from the registrant’s proxy statement for the annual meeting of stockholders, which proxy statement was filed with the Securities and Exchange Commission on August 28, 2023.
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	true
Document Financial Statement Restatement Recovery Analysis [Flag]	false
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	Irvine, California

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 30, 2023	Apr. 30, 2022
Current assets:
Cash and cash equivalents	$ 38,542	$ 126,166
Accounts receivable, net	18,298	20,547
Contract assets	9,609	5,369
Inventory	43,908	26,062
Prepaid expenses and other current assets	2,094	1,879
Total current assets	112,451	180,023
Property and equipment, net	177,770	92,955
Operating lease right-of-use assets	42,772	36,806
Deferred tax assets	113,751	115,082
Other assets	4,473	4,627
Restricted cash	350	350
Total assets	451,567	429,843
Current liabilities:
Accounts payable	24,593	9,504
Accrued compensation and benefits	8,780	8,418
Contract liabilities	37,352	53,798
Convertible senior notes, net	140,623	0
Current portion of operating lease liabilities	1,358	2,969
Other current liabilities	2,440	1,072
Total current liabilities	215,146	75,761
Convertible senior notes, net		139,577
Operating lease liabilities, less current portion	45,690	37,886
Finance lease liabilities, less current portion	1,562	2,093
Total liabilities	262,398	255,317
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates	0	0
Common stock, $0.001 par value; 150,000 shares authorized; 62,692 and 61,807 shares issued and outstanding at respective dates	63	62
Additional paid-in capital	620,224	605,841
Accumulated deficit	(431,118)	(431,377)
Total stockholders’ equity	189,169	174,526
Total liabilities and stockholders’ equity	$ 451,567	$ 429,843

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Apr. 30, 2023	Apr. 30, 2022
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000	150,000
Common stock, shares issued	62,692	61,807
Common stock, shares outstanding	62,692	61,807

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Income Statement [Abstract]
Revenues	$ 149,266	$ 119,597	$ 95,868
Cost of revenues	117,786	82,949	66,561
Gross profit	31,480	36,648	29,307
Operating expenses:
Selling, general and administrative	27,879	21,226	17,064
Total operating expenses	27,879	21,226	17,064
Operating income	3,601	15,422	12,243
Interest expense	(3,013)	(2,680)	(1,164)
Other income (expense), net	1,002	(81)	133
Net income before income taxes	1,590	12,661	11,212
Income tax expense (benefit)	1,331	(115,011)	0
Net income	259	127,672	11,212
Comprehensive income	259	127,672	11,212
Series E preferred stock accumulated dividends	0	0	(4,455)
Impact of Series E preferred stock redemption	0	0	(3,439)
Net income attributable to common stockholders	$ 259	$ 127,672	$ 3,318
Net income per share attributable to common stockholders:
Basic	$ 0	$ 2.08	$ 0.06
Diluted	$ 0	$ 1.84	$ 0.06
Weighted average common shares outstanding:
Basic	62,268	61,484	58,222
Diluted	63,782	70,474	59,426

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Apr. 30, 2020	$ 2	$ 56	$ 612,909	$ (571,071)	$ 41,896
Beginning balance, shares at Apr. 30, 2020	1,648	56,483
Series E preferred stock dividends paid ($2.705 per share)			$ (4,455)		$ (4,455)
Conversion of Series E preferred stock to common stock
Conversion of Series E preferred stock to common stock, shares	(28)	(34)
Conversion of Series E preferred stock to common stock, shares	28	34
Redemption of Series E preferred stock	$ (2)		$ (40,488)		$ (40,490)
Redemption of Series E preferred stock, shares	(1,620)
Common stock issued, net of issuance costs of $2,359		$ 4	32,137		32,141
Common stock issued, net of issuance costs of $2,359, shares		3,833
Common stock issued under equity compensation plans		$ 1	3,983		3,984
Common stock issued under equity compensation plans, shares		719
Equity component of convertible senior notes			42,431		42,431
Purchase of capped calls related to convertible senior notes			(12,837)		(12,837)
Stock-based compensation expense			3,854		3,854
Net income (as restated)				11,212	11,212
Balances at April 30, 2023 (as restated) at Apr. 30, 2021		$ 61	637,534	(559,859)	77,736
Ending balance, shares at Apr. 30, 2021		61,069
Cumulative-effect adjustment from modified retrospective adoption of ASU 2020-06			(42,431)	810	(41,621)
Common stock issued under equity compensation plans		$ 1	3,358		3,359
Common stock issued under equity compensation plans, shares		738
Stock-based compensation expense			7,380		7,380
Net income (as restated)				127,672	127,672
Balances at April 30, 2023 (as restated) at Apr. 30, 2022		$ 62	605,841	(431,377)	174,526
Ending balance, shares at Apr. 30, 2022		61,807
Common stock issued under equity compensation plans					1,012
Stock-based compensation expense					1,897
Net income (as restated)					1,361
Balances at April 30, 2023 (as restated) at Jul. 31, 2022					178,796
Beginning balance, value at Apr. 30, 2022		$ 62	605,841	(431,377)	174,526
Beginning balance, shares at Apr. 30, 2022		61,807
Common stock issued under equity compensation plans					1,578
Stock-based compensation expense					4,683
Net income (as restated)					841
Balances at April 30, 2023 (as restated) at Oct. 31, 2022				(430,536)	181,628
Beginning balance, value at Apr. 30, 2022		$ 62	605,841	(431,377)	174,526
Beginning balance, shares at Apr. 30, 2022		61,807
Common stock issued under equity compensation plans					2,573
Stock-based compensation expense					7,427
Net income (as restated)				594	594
Balances at April 30, 2023 (as restated) at Jan. 31, 2023				(430,783)	185,120
Beginning balance, value at Apr. 30, 2022		$ 62	605,841	(431,377)	174,526
Beginning balance, shares at Apr. 30, 2022		61,807
Common stock issued under equity compensation plans		$ 1	3,405		3,406
Common stock issued under equity compensation plans, shares		885
Stock-based compensation expense			10,978		10,978
Net income (as restated)				259	259
Balances at April 30, 2023 (as restated) at Apr. 30, 2023		$ 63	$ 620,224	(431,118)	189,169
Ending balance, shares at Apr. 30, 2023		62,692
Beginning balance, value at Jul. 31, 2022					178,796
Common stock issued under equity compensation plans					566
Stock-based compensation expense					2,786
Net income (as restated)					(520)
Balances at April 30, 2023 (as restated) at Oct. 31, 2022				(430,536)	181,628
Common stock issued under equity compensation plans					995
Stock-based compensation expense					2,744
Net income (as restated)				(247)	(247)
Balances at April 30, 2023 (as restated) at Jan. 31, 2023				$ (430,783)	$ 185,120

CONSOLIDATED STATEMENTS OF ST_2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	12 Months Ended
	Apr. 30, 2021 USD ($) $ / shares
Statement of Stockholders' Equity [Abstract]
Preferred Stock, Dividends, Per Share, Cash Paid | $ / shares	$ 2.705
Payment of stock issuance costs | $	$ 2,359

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 259	$ 127,672	$ 11,212
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Stock-based compensation	10,978	7,380	3,854
Depreciation and amortization	7,210	4,480	3,453
Amortization of debt discount and issuance costs	1,046	1,030	916
Deferred income taxes	1,331	(115,082)	0
Loss on disposal and/or impairment of property and equipment	139	381	0
Changes in operating assets and liabilities:
Accounts receivable, net	2,249	(1,705)	(10,236)
Contract assets	(4,240)	743	(2,812)
Inventory	(17,846)	(14,191)	(988)
Prepaid expenses and other assets	(61)	(4,232)	(1,260)
Accounts payable	964	(943)	(608)
Accrued compensation and benefits	362	(376)	5,775
Contract liabilities	(16,446)	3,029	21,649
Other accrued expenses and liabilities	1,333	1,279	227
Net cash (used in) provided by operating activities	(12,722)	9,465	31,182
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(77,803)	(56,411)	(9,864)
Net cash used in investing activities	(77,803)	(56,411)	(9,864)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under equity compensation plans	3,406	3,359	3,984
Proceeds from issuance of common stock, net of issuance costs	0	0	32,141
Proceeds from issuance of convertible senior notes, net of issuance costs	0	0	138,464
Purchases of capped calls related to convertible senior notes	0	0	(12,837)
Repayment of note payable	0	0	(4,379)
Dividends paid on preferred stock	0	0	(4,455)
Redemption of preferred stock	0	0	(37,051)
Impact of preferred stock redemption	0	0	(3,439)
Principal payments on finance leases	(505)	(162)	(93)
Net cash provided by financing activities	2,901	3,197	112,335
Net (decrease) increase in cash, cash equivalents and restricted cash	(87,624)	(43,749)	133,653
Cash, cash equivalents and restricted cash, beginning of period	126,516	170,265	36,612
Cash, cash equivalents and restricted cash, end of period	38,892	126,516	170,265
Supplemental disclosures of cash flow information:
Cash paid for interest	1,118	1,670	5
Cash paid for income taxes	260	64	0
Supplemental disclosures of non-cash activities:
Unpaid purchases of property and equipment	$ 14,361	$ 1,190	$ 3,939

Description of Company and Basi

Description of Company and Basis of Presentation	12 Months Ended
	Apr. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Company and Basis of Presentation	Note 1 – Description of Company and Basis of Presentation We are a dedicated contract development and manufacturing organization (“CDMO”) that provides a comprehensive range of services from process development to Current Good Manufacturing Practices (“CGMP”) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. Except where specifically noted or the context otherwise requires, references to “Avid,” the “Company,” “we,” “us,” and “our,” in this Amended Report refer to Avid Bioservices, Inc. and its subsidiary. Basis of Presentation and Preparation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include our accounts and those of our subsidiary. All intercompany accounts and transactions among the consolidated entities have been eliminated in the consolidated financial statements. The preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management’s estimates are based on historical information available as of the date of the consolidated financial statements and on various other assumptions that are believed to be reasonable under the circumstances. Accounting estimates and judgments are inherently uncertain and actual results could differ materially from these estimates. Segment Reporting Our business operates in one operating segment, our contract manufacturing and development services segment. Accordingly, we reported our financial results for one reportable segment Restatement of Previously Issued Consolidated Financial Statements On February 29, 2024, we received an acceleration notice (the “Acceleration Notice”) from a holder of our 1.250% Exchangeable Senior Notes due 2026 (the “2026 Notes”). The Acceleration Notice stipulated, among other things, that (i) we did not remove the restrictive legend on the 2026 Notes by March 17, 2022 as required under the indenture governing the 2026 Notes (the “2026 Notes Indenture”), (ii) due to such failure, additional interest had accrued thereafter at a rate of 0.50% per annum (the “Additional Interest”), (iii) such Additional Interest had not been paid by us as of the date of the Acceleration Notice, which constitutes an event of default under the 2026 Notes Indenture (the “Event of Default”), and (iv) such holder was the beneficial owner of at least 25% in aggregate principal amount of the outstanding 2026 Notes and therefore had the right to accelerate all of the 2026 Notes. such holder declared 100% of the principal amount of, and accrued and unpaid interest on, the 2026 Notes to be due and payable immediately. Following the receipt of the Acceleration Notice and a re-evaluation of the accounting for the 2026 Notes, we determined that the 2026 Notes should have been classified as a current liability beginning on October 15, 2022, resulting in an understatement of current liabilities on our consolidated balance sheet. The re-classification of the 2026 Notes to a current liability resulted in negative working capital and created a substantial doubt regarding our ability to continue as a going concern. However, this substantial doubt has been resolved through the subsequent issuance of the 2029 Notes, as further described in Note 11, Subsequent Events The impact on the line items within our consolidated financial statements as of and for the fiscal year ended April 30, 2023 previously filed in our Annual Report on Form 10-K for the fiscal year ended April 30, 2023 are as follows (in thousands, except par value and per share information): Schedule of consolidated financial statements As of April 30, 2023 Consolidated Balance Sheet (as reported) (adjustments) (as restated) ASSETS Current assets: Cash and cash equivalents $ 38,542 $ – $ 38,542 Accounts receivable, net 18,298 – 18,298 Contract assets 9,609 – 9,609 Inventory 43,908 – 43,908 Prepaid expenses and other current assets 2,094 – 2,094 Total current assets 112,451 – 112,451 Property and equipment, net 177,369 401 177,770 Operating lease right-of-use assets 42,772 – 42,772 Deferred tax assets 113,639 112 113,751 Other assets 4,473 – 4,473 Restricted cash 350 – 350 Total assets $ 451,054 $ 513 $ 451,567 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 24,593 $ – $ 24,593 Accrued compensation and benefits 8,780 – 8,780 Contract liabilities 37,352 – 37,352 Convertible senior notes, net – 140,623 140,623 Current portion of operating lease liabilities 1,358 – 1,358 Other current liabilities 1,626 814 2,440 Total current liabilities 73,709 141,437 215,146 Convertible senior notes, net 140,623 (140,623 ) – Operating lease liabilities, less current portion 45,690 – 45,690 Finance lease liabilities, less current portion 1,562 – 1,562 Total liabilities 261,584 814 262,398 Commitments and contingencies – – – Stockholders’ equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates – – – Common stock, $0.001 par value; 150,000 shares authorized; 62,692 and 61,807 shares issued and outstanding at respective dates 63 – 63 Additional paid-in capital 620,224 – 620,224 Accumulated deficit (430,817 ) (301 ) (431,118 ) Total stockholders’ equity 189,470 (301 ) 189,169 Total liabilities and stockholders’ equity $ 451,054 $ 513 $ 451,567 Schedule of consolidated statement of income and comprehensive income Year Ended April 30, 2023 Consolidated Statement of Income and Comprehensive Income (as reported) (adjustments) (as restated) Revenues $ 149,266 $ – $ 149,266 Cost of revenues 117,786 – 117,786 Gross profit 31,480 – 31,480 Operating expenses: Selling, general and administrative 27,879 – 27,879 Total operating expenses 27,879 – 27,879 Operating income 3,601 – 3,601 Interest expense (2,600 ) (413 ) (3,013 ) Other income, net 1,002 – 1,002 Net income before income taxes 2,003 (413 ) 1,590 Income tax expense 1,443 (112 ) 1,331 Net income $ 560 $ (301 ) $ 259 Comprehensive income $ 560 $ (301 ) $ 259 Net income per share: Basic $ 0.01 $ (0.01 ) $ 0.00 Diluted $ 0.01 $ (0.01 ) $ 0.00 Weighted average common shares outstanding: Basic 62,268 – 62,268 Diluted 63,782 – 63,782 Schedule of condensed consolidated statement of stockholders’ equity Year Ended April 30, 2023 Accumulated Deficit Total Stockholders’ Equity Adjustments Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at April 30, 2022 $ (431,377 ) $ 174,526 $ – $ (431,377 ) $ 174,526 Common stock issued under equity compensation plans – 3,406 – – 3,406 Stock-based compensation expense – 10,978 – – 10,978 Net income 560 560 (301 ) 259 259 Balances at April 30, 2023 $ (430,817 ) $ 189,470 $ (301 ) $ (431,118 ) $ 189,169 Schedule of consolidated statement of cash flows Year Ended April 30, 2023 Consolidated Statement of Cash Flows (as reported) (adjustments) (as restated) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 560 $ (301 ) $ 259 Adjustments to reconcile net income to net cash used in operating activities: Stock-based compensation 10,978 – 10,978 Depreciation and amortization 7,210 – 7,210 Amortization of debt issuance costs 1,046 – 1,046 Deferred income taxes 1,443 (112 ) 1,331 Loss on disposal and/or impairment of property and equipment 139 – 139 Changes in operating assets and liabilities: Accounts receivable, net 2,249 – 2,249 Contract assets (4,240 ) – (4,240 ) Inventory (17,846 ) – (17,846 ) Prepaid expenses and other assets (61 ) – (61 ) Accounts payable 964 – 964 Accrued compensation and benefits 362 – 362 Contract liabilities (16,446 ) – (16,446 ) Other accrued expenses and liabilities 755 578 1,333 Net cash used in operating activities (12,887 ) 165 (12,722 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (77,638 ) (165 ) (77,803 ) Net cash used in investing activities (77,638 ) (165 ) (77,803 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock under equity compensation plans 3,406 – 3,406 Principal payments on finance leases (505 ) – (505 ) Net cash provided by financing activities 2,901 – 2,901 Net decrease in cash, cash equivalents and restricted cash (87,624 ) – (87,624 ) Cash, cash equivalents and restricted cash, beginning of period 126,516 – 126,516 Cash, cash equivalents and restricted cash, end of period $ 38,892 – $ 38,892 Supplemental disclosures of cash flow information: Cash paid for interest $ 1,118 $ – $ 1,118 Cash paid for income taxes $ 260 $ – $ 260 Supplemental disclosures of non-cash activities: Unpaid purchases of property and equipment $ 14,125 $ 236 $ 14,361

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Apr. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Cash and Cash Equivalents We consider all short-term investments readily convertible to cash, without notice or penalty, with an initial maturity of 90 days or less to be cash equivalents. Restricted Cash Under the terms of an operating lease related to one of our facilities (Note 4), we are required to maintain a letter of credit as collateral. Accordingly, at April 30, 2023 and 2022, restricted cash of $ 0.4 million The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Schedule of restricted cash As of April 30, 2023 2022 2021 Cash and cash equivalents $ 38,542 $ 126,166 $ 169,915 Restricted cash 350 350 350 Total cash, cash equivalents and restricted cash $ 38,892 $ 126,516 $ 170,265 Revenue Recognition We recognize revenue in accordance with the authoritative guidance of ASC 606, Revenue from Contracts with Customers Revenue recognized from services provided under our customer contracts is disaggregated into manufacturing and process development revenue streams. Manufacturing revenue Manufacturing revenue generally represents revenue from the manufacturing of customer products recognized over time utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimates for the entire cost of the performance obligation. Under a manufacturing contract, a quantity of manufacturing runs are ordered at a specified scale with prescribed delivery dates, where the product is manufactured according to the customer’s specifications and typically includes only one performance obligation. Each manufacturing run represents a distinct service that is sold separately and has stand-alone value to the customer. The products are manufactured exclusively for a specific customer and have no alternative use. The customer retains control of its product during the entire manufacturing process and can make changes to the process or specifications at its request. Under these agreements, we are entitled to consideration for progress to date that includes an element of profit margin. Process development revenue Process development revenue generally represents revenue from services associated with the custom development of a manufacturing process and analytical methods for a customer’s product. Process development revenue is recognized over time utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimates for the entire cost of the performance obligation. Under a process development contract, the customer owns the product details and process, which has no alternative use. These process development projects are customized to each customer to meet its specifications and typically includes only one performance obligation. Each process represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by our services and can make changes to its process or specifications upon request. Under these agreements, we are entitled to consideration for progress to date that includes an element of profit margin. The following table summarizes our manufacturing and process development revenue streams (in thousands): Disaggregation of revenue Fiscal Year Ended April 30, 2023 2022 2021 Manufacturing revenues $ 125,416 $ 99,282 $ 83,678 Process development revenues 23,850 20,315 12,190 Total revenues $ 149,266 $ 119,597 $ 95,868 The timing of revenue recognition, billings and cash collections results in billed accounts receivable, contract assets (unbilled receivables), and contract liabilities (customer deposits and deferred revenue). Contract assets are recorded when our right to consideration is conditioned on something other than the passage of time. Contract assets are reclassified to accounts receivable on the consolidated balance sheet when our rights become unconditional. Contract liabilities represent customer deposits and deferred revenue billed and/or received in advance of our fulfillment of performance obligations. Contract liabilities convert to revenue as we perform our obligations under the contract. During the fiscal years ended April 30, 2023 and 2022, we recognized revenue of $ 40.8 million 34 The transaction price for services provided under our customer contracts reflects our best estimates of the amount of consideration to which we are entitled in exchange for providing goods and services to our customers. For contracts with multiple performance obligations, we allocate transaction price to each performance obligation identified in a contract on a relative standalone selling price basis. We generally determine relative standalone selling prices based on the price observed in the customer contract for each distinct performance obligation. If observable standalone selling prices are not available, we may estimate the applicable standalone selling price based on the pricing of other comparable services or on a price that we believe the market is willing to pay for the applicable service. In determining the transaction price, we also considered the different sources of variable consideration including, but not limited to, discounts, credits, refunds, price concessions or other similar items. We have included in the transaction price some or all of an amount of variable consideration, utilizing the most likely method, only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The actual amount of consideration ultimately received may differ. In addition, our customer contracts generally include provisions entitling us to a cancellation or postponement fee when a customer cancels or postpones its commitments prior to our initiation of services, therefore not utilizing their reserved capacity. The determination of such cancellation and postponement fees are based on the terms stated in the related customer contract but are generally considered substantive for accounting purposes and create an enforceable right and obligation due to us when the cancellation or postponement occurs. Accordingly, we recognize such fees, subject to variable consideration, as revenue upon the cancellation or postponement date utilizing the most likely method. Management may be required to exercise judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations, estimating variable consideration, and estimating the progress towards the satisfaction of performance obligations. If actual results in the future vary from our estimates, the estimates will be adjusted, which will affect revenues in the period that such variances become known. During the fiscal year ended April 30, 2023, we recognized revenue of $ 3.0 million 14.7 million We apply the practical expedient available under ASC 606 that permits us not to disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. As of April 30, 2023, we do not have any unsatisfied performance obligations for contracts greater than one year. Costs incurred to obtain a contract are not material. These costs are generally employee sales commissions, which are expensed as incurred and included in selling, general and administrative expense in the consolidated statements of income and comprehensive income. Accounts Receivable, Net Accounts receivable is primarily comprised of amounts owed to us for services provided under our customer contracts and are recorded at the invoiced amount net of an allowance for doubtful accounts, if necessary. We apply judgment in assessing the ultimate realization of our receivables and we estimate an allowance for doubtful accounts based on various factors, such as the aging of our receivables, historical experience, and the financial condition of our customers. Based on our analysis of our accounts receivable balance as of April 30, 2023, we determined an allowance for doubtful accounts of $ 0.5 million Based on our analysis of our accounts receivable balance as of April 30, 2022, we determined an allowance for doubtful accounts of $ 18.4 million Concentrations of Credit Risk and Customer Base Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents, accounts receivable, net and contract assets. As of April 30, 2023 and 2022, we maintain our cash balances primarily with a major commercial bank and our deposits held with the bank exceed the amount of government insurance limits provided on our deposits. We are exposed to credit risk in the event of default by the major commercial bank holding our cash balances to the extent of the cash amounts recorded on the accompanying consolidated balance sheets exceed the amount of government insurance limits provided on our deposits. Our accounts receivable from amounts billed for services provided under customer contracts are derived from a limited number of customers. Most customer contracts require up-front payments and installment payments during the service period. We perform periodic evaluations of the financial condition of our customers and generally do not require collateral, but we can terminate any contract if a material default occurs. At April 30, 2023 and 2022, approximately 76% and 84%, respectively, of our accounts receivable, net were due from our top ten customers. Our revenues are derived from a limited number of customers. Historically, these customers have not entered into long-term contracts because their need for drug supply depends on a variety of factors, including a product’s stage of development, the timing of regulatory filings and approvals, the product needs of their collaborators, if applicable, their financial resources and the market demand with respect to a commercial product. The table below identifies each of our customers that accounted for 10% or more of our total revenues during any of the fiscal years ended April 30, 2023, 2022 and 2021: Concentration of revenues Customer Geographic Location 2023 2022 2021 Halozyme Therapeutics, Inc. (1) U.S. 53 % 41 % 51 % IGM Biosciences, Inc. U.S. * 11 * Gilead Sciences, Inc. U.S. – * 16 ______________ (1) Revenues are derived from the manufacture of multiple therapeutics that our customer uses in various products and product candidates. * Represents a percentage less than 10% of our total revenues. We attribute revenue to the individual countries where the customer is headquartered. Approximately 100 Leases We account for our leases in accordance with the authoritative guidance of ASC 842, Leases Our operating leases may include options to extend the lease which are included in the lease term when it is reasonably certain that we will exercise a renewal option. Operating lease expense is recognized on a straight-line basis over the expected lease term. Our finance lease with a term greater than one year is included as an asset within property and equipment, net and a lease liability equal to the present value of the minimum lease payments is included in other current liabilities and finance lease liabilities, less current portion in our consolidated balance sheets. The present value of the finance lease payments is calculated using the implicit interest rate in the lease. Finance lease ROU assets are amortized on a straight-line basis over the expected useful life of the asset and the carrying amount of the lease liability is adjusted to reflect interest, which is recorded as interest expense. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets and lease expense for these short-term leases is recognized on a straight-line basis over the lease term. We have also elected the practical expedient to not separate lease components from non-lease components. Inventory Inventory consists of raw materials inventory and is valued at the lower of cost, determined by the first-in, first-out method, or net realizable value. We periodically review raw materials inventory for potential impairment and adjust inventory to its net realizable value based on the estimate of future use and reduce the carrying value of inventory as deemed necessary. Property and Equipment Property and equipment is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the related asset, which are generally as follows: Schedule of estimated useful lives of property Description Estimated Useful Life Leasehold improvements Shorter of estimated useful life or lease term Laboratory and manufacturing equipment 5 – 15 years Computer equipment and software 3 – 5 years Furniture, fixtures and office equipment 5 – 10 years Costs for property and equipment not yet placed into service have been capitalized as construction-in-progress. These costs are primarily related to equipment and leasehold improvements associated with our manufacturing facilities, and will be depreciated in accordance with the above guidelines once placed into service. Interest costs incurred during construction of major capital projects are capitalized as construction-in-progress until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Interest capitalized as construction-in-progress for the fiscal years ended April 30, 2023 and 2022, was $ 0.8 million 0.2 million Schedule of property and equipment April 30, 2023 2022 (as restated) Leasehold improvements $ 97,514 $ 37,345 Laboratory and manufacturing equipment 35,501 30,089 Computer equipment and software 5,028 5,326 Furniture, fixtures and office equipment 1,681 843 Construction-in-progress 68,414 43,809 Total property and equipment, gross 208,138 117,412 Less: accumulated depreciation and amortization (30,368 ) (24,457 ) Total property and equipment, net $ 177,770 $ 92,955 Depreciation and amortization expense for the fiscal years ended April 30, 2023, 2022 and 2021 was $ 7.2 million 4.5 million 3.5 million Capitalized Software Implementation Cost We capitalize certain implementation costs incurred under cloud computing hosting arrangements. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within other assets on the accompanying consolidated balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred. Impairment Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. If such events or changes in circumstances arise, we compare the carrying amount of the long-lived assets to the estimated future undiscounted cash flows expected to be generated by the long-lived assets. If the long-lived assets are determined to be impaired, any excess of the carrying value of the long-lived assets over its estimated fair value is recognized as an impairment loss. For the fiscal year ended April 30, 2023, there were indicators of impairment of the value of certain long-lived assets that resulted in an impairment loss of $ 0.1 million no Fair Value of Financial Instruments The carrying amounts in the accompanying consolidated balance sheets for cash and cash equivalents, restricted cash, accounts receivable, net, accounts payable and accrued liabilities approximate their fair values due to their short-term maturities. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy: · Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities. · Level 2 – Observable inputs other than quoted prices included in Level 1, such as assets or liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. · Level 3 – Unobservable inputs that are supported by little or no market activity and significant to the overall fair value measurement of the assets or liabilities; therefore requiring the company to develop its own valuation techniques and assumptions. As of April 30, 2023 and 2022, we did not have any Level 2 or Level 3 financial assets and our cash equivalents of $ 28.7 million 116.3 million Stock-Based Compensation We account for stock options, restricted stock units, performance stock units and other stock-based awards granted under our equity compensation plans in accordance with the authoritative guidance of ASC 718, Compensation – Stock Compensation Debt Issuance Costs Debt issuance costs related to convertible senior notes are recorded as a deduction that is netted against the principal value of the debt and are amortized to interest expense using the effective interest method over the contractual term of the debt (Note 3). Debt issuance costs related to the revolving credit facility are included in prepaid expenses and other current assets in the consolidated balance sheet at April 30, 2023 and are amortized to interest expense over the contractual term of the revolving credit facility (Note 3). Advertising Costs Advertising costs are expensed as incurred and included in selling, general and administrative expenses in the consolidated statements of income and comprehensive income. For the fiscal years ended April 30, 2023, 2022 and 2021, advertising costs were $ 0.7 million 0.6 million 0.3 million Income Taxes We utilize the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes 115 We are required to file federal and state income tax returns in various jurisdictions. The preparation of these returns requires us to interpret the applicable tax laws in effect in such jurisdictions, which could affect the amount paid by us. Comprehensive Income Comprehensive income is the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income is equal to our net income for all periods presented. Accounting Standards Not Yet Adopted In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates

Debt (as restated)

Debt (as restated)	12 Months Ended
	Apr. 30, 2023
Debt Disclosure [Abstract]
Debt (as restated)	Note 3 – Debt (as restated) Convertible Senior Notes Due 2026 In March 2021, we issued $ 143.8 million 138.5 million 5.3 million The 2026 Notes are senior unsecured obligations and accrue interest at a rate of 1.25 March 15, 2026 The initial conversion rate for the 2026 Notes is approximately 47.1403 shares of our common stock per $1,000 principal amount, which represents an initial conversion price of approximately $21.21 per share of our common stock. The conversion rate is subject to adjustments upon the occurrence of certain events in accordance with the terms of the 2026 Notes Indenture. In addition, following certain corporate events that occur prior to the maturity date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert their 2026 Notes in connection with such a fundamental change, as defined in the 2026 Notes Indenture. Holders of the 2026 Notes may convert their 2026 Notes at their option at any time prior to the close of business on the business day immediately preceding September 15, 2025, only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending July 31, 2021, if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the 2026 Notes Indenture) per $1,000 principal amount of the 2026 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the exchange rate on each such trading day; (3) if we call any or all of the 2026 Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; and (4) upon the occurrence of specified corporate events as described in the Indenture. On or after September 15, 2025 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders at their option may convert their 2026 Notes at any time, regardless of the foregoing circumstances. We may not redeem the 2026 Notes prior to March 20, 2024. On or after March 20, 2024, the 2026 Notes are redeemable for cash, whole or in part, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If we undergo a fundamental change (as defined in the 2026 Notes Indenture), holders may require us to repurchase for cash all or any portion of their 2026 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2026 Notes to be repurchased, plus accrued and unpaid interest to, but excluding the redemption date. The 2026 Notes Indenture contains customary terms and covenants, including that upon certain events of default occurring and continuing, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding 2026 Notes may declare the entire principal of all the 2026 Notes plus accrued and unpaid interest to be immediately due and payable. As described in Note 1, on February 29, 2024, as a result of the Event of Default, a holder of at least 25% aggregate principal amount of 2026 Notes declared 100% of the principal amount of, and accrued and unpaid interest on, the 2026 Notes to be due and payable immediately. Furthermore, due to the Event of Default, conditions allowing the trustee or the holders of at least 25% in aggregate principal amount of the outstanding 2026 Notes to declare the entire principal of the outstanding 2026 Notes to be immediately due and payable had been met as of October 15, 2022 and, therefore, the 2026 Notes are classified as a current liability on the consolidated balance sheet at April 30, 2023. As of April 30, 2022, the conditions allowing holders of the 2026 Notes to convert had not been met and, therefore, the 2026 Notes are classified as a long-term liability on the consolidated balance sheet at April 30, 2022. Refer also to Note 11, Subsequent Events In accounting for the issuance of the 2026 Notes, prior to the adoption of ASU 2020-06, Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity 99.7 million 8.78 44.1 million In accounting for the issuance costs related to the 2026 Notes, prior to the adoption of ASU 2020-06, we allocated the total amount incurred to the debt and equity components of the 2026 Notes based on their relative values. Issuance costs attributable to the debt component were $ 3.7 million 1.6 million On May 1, 2021, we elected to early adopt ASU 2020-06 using the modified retrospective transition method. Under such transition method, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to our adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the re-combination of the debt and equity components of the 2026 Notes into a single debt instrument, which resulted in a $42.4 million decrease in additional paid-in capital from the derecognition of the bifurcated equity component, a $41.6 million increase in convertible senior notes, net from the derecognition of the discount associated with the bifurcated equity component, or debt discount, and $0.8 million decrease to the May 1, 2021 opening balance of accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2026 Notes. Additionally, we derecognized the allocation of the issuance costs to the equity component and all issuance costs related to the 2026 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2026 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The net carrying amount of the 2026 Notes is as follows (in thousands): Schedule of net carrying amount of the debt component April 30, 2023 April 30, 2022 Principal $ 143,750 $ 143,750 Unamortized issuance costs (3,127 ) (4,173 ) Net carrying amount $ 140,623 $ 139,577 As of April 30, 2023 and 2022, the estimated fair value of the 2026 Notes was approximately $ 157.3 million 167.1 million 100 The following table summarizes the interest expense recognized related to the 2026 Notes for the fiscal years ended April 30, 2023, 2022 and 2021 (in thousands): Schedule of interest expenses Fiscal Year Ended April 30, 2023 2022 2021 (as restated) Contractual interest expense $ 1,808 $ 1,603 $ 245 Amortization of issuance costs 1,046 1,030 54 Amortization of debt discount (1) – – 862 Total interest expense associated with 2026 Notes $ 2,854 $ 2,633 $ 1,161 _______________ (1) As discussed above, the adoption of ASU 2020-06 on May 1, 2021 resulted in the re-combination of the debt and equity components of the 2026 Notes into a single debt instrument. Accordingly, the unamortized debt discount balance and the net carrying amount of the equity component were derecognized. The effective annual interest rate of the 2026 Notes for the fiscal years ended April 30, 2023, 2022 and 2021 was 2.31%, 2.03%, and 9.65%, respectively. The effective annual interest rate is computed using the contractual interest and the amortization of debt issuance costs. However, due to the Event of Default as described in Note 1, the fiscal year ended April 30, 2023 contractual interest rate also included an additional interest rate and a default interest rate. In addition, prior to the adoption of ASU 2020-06 on May 1, 2021, the effective annual interest rate calculation also included the amortization of the debt discount. Capped Call Transactions In connection with the issuance of the 2026 Notes, we entered into privately negotiated capped call transactions (the “Capped Calls”) with certain financial institution counterparties (the “Option Counterparties”). We used $12.8 million of the net proceeds from the issuance of the 2026 Notes to pay the cost of the Capped Calls. The Capped Calls cover, subject to customary anti-dilution adjustments, the aggregate number of shares of our common stock that initially underlie the 2026 Notes, and are generally expected to reduce the potential dilution of our common stock upon any conversion of the 2026 Notes, as the case may be, with such reduction and/or offset subject to a cap, based on the cap price of the Capped Calls. The cap share price of the Capped Calls is approximately $28.02 per share, which represents a premium of 75% over the last reported sale price of our common stock on March 9, 2021 and is subject to certain adjustments under the terms of the Capped Calls. However, there would nevertheless be dilution upon conversion of the 2026 Notes to the extent that such market price exceeds the capped share price as measured under the terms of the Capped Calls. We evaluated the Capped Calls under ASC 815-10 and determined that they should be accounted for as a separate transaction from the 2026 Notes and that the Capped Calls met the criteria for equity classification. Therefore, the cost of $12.8 million to purchase the Capped Calls was recorded as a reduction to additional paid-in capital in the consolidated balance sheet at April 30, 2021. The Capped Calls will not be subsequently remeasured as long as the conditions for equity classification continue to be met. During fiscal years 2023 and 2022, there were no conversions of our 2026 Notes, and therefore, there was no activity with respect to the Capped Calls. We believe the conditions for equity classification continue to be met as of April 30, 2023 and 2022. As described in Note 11, during March 2024, in connection with our repurchase and payoff of the remaining balance of the 2026 Notes we entered into transactions to unwind all of our Capped Calls. As a result, we received $1.3 million in net proceeds from the unwinding of the Capped Calls. Revolving Credit Facility On March 14, 2023, we entered into a credit agreement with Bank of America, N.A., as administrative agent and letter of credit issuer, which was subsequently amended on October 27, 2023 (as amended, the “Credit Agreement”). The Credit Agreement provides for a revolving credit facility (the “Revolving Credit Facility”) in an amount equal to the lesser of (i) $50 million, and (ii) a borrowing base calculated as the sum of (a) 80% of the value of certain of our eligible accounts receivable, plus (b) up to 100% of the value of eligible cash collateral. The Revolving Credit Facility will mature on October 25, 2024 and is secured by substantially all of our assets. no As a result of the Acceleration Event associated with the 2026 Notes (Note 1), such occurrence resulted in a cross-default under our Credit Agreement. On March 12, 2024, we entered into Amendment No. 2 to the Credit Agreement which, among other things, (i) waives the events of default under the Credit Agreement as a result of the acceleration of our 2026 Notes, (ii) permits the issuance of our 2029 Notes and the repayment of our 2026 Notes (Note 11) and (iii) adjusts the financial covenant in the Credit Agreement. Loans under the Revolving Credit Facility will bear interest at either (1) a term Secured Overnight Financing Rate (“SOFR”) rate for a specified interest period plus a SOFR adjustment (equal to 0.10%) plus a margin of 1.60% or (2) base rate plus a margin of 0.60% at our option. 0.25 The Credit Agreement includes certain customary affirmative and negative covenants, including limitations on mergers, consolidations and sales of assets, limitations on liens, limitations on certain restricted payments and investments, limitations on transactions with affiliates and limitations on incurring additional indebtedness. In addition, the Credit Agreement requires maintenance of a minimum consolidated EBITDA, as defined in the Credit Agreement, of $ 15 The Credit Agreement also provides for certain customary events of defaults, including, among others, failure to make payments, breach of representations and warranties, and default of covenants.

Leases

Leases	12 Months Ended
	Apr. 30, 2023
Leases
Leases	Note 4 – Leases We currently lease certain office, manufacturing, laboratory and warehouse space located in Orange County, California under operating lease agreements. Our leased facilities have original lease terms ranging from 7 to 12 years, contain multi-year renewal options, and scheduled rent increases of 3% on either an annual or biennial basis. Multi-year renewal options were included in determining the right-of-use asset and lease liability for three of our leases as we considered it reasonably certain that we would exercise such renewal options. In addition, certain of our leases provide for periods of free rent, lessor improvements and tenant improvement allowances, of which certain of these improvements have been classified as leasehold improvements and/or are being amortized over the shorter of the estimated useful life of the improvements or the remaining life of the lease. Certain of our operating facility leases require us to pay property taxes, insurance and common area maintenance. While these payments are not included as part of our lease liabilities, they are recognized as variable lease cost in the period they are incurred. We also lease certain manufacturing equipment under a 5-year finance lease that commenced in the second quarter of fiscal year 2022. The components of our lease costs for the fiscal years ended April 30, 2023, 2022 and 2021, were as follows (in thousands): Schedule of lease costs Fiscal Year Ended April 30, 2023 2022 2021 Operating lease cost $ 4,386 $ 3,872 $ 3,151 Variable lease cost 1,408 944 676 Short-term lease cost 576 515 388 Finance lease costs: Amortization of right-of-use assets 216 43 82 Interest on lease liabilities 125 47 4 Total lease costs $ 6,711 $ 5,421 $ 4,301 Supplemental consolidated balance sheet and other information related to our leases as of April 30, 2023 and 2022 were as follows (in thousands, except weighted average data): Balance sheet classification of leases April 30, Leases Classification 2023 2022 Assets Operating Operating lease right-of-use assets $ 42,772 $ 36,806 Finance Property and equipment, net 2,529 2,728 Total leased assets $ 45,301 $ 39,534 Liabilities Current: Operating Current portion of operating lease liabilities $ 1,358 $ 2,969 Finance Other current liabilities 531 505 Non-current: Operating Operating lease liabilities, less current portion 45,690 37,886 Finance Finance lease liabilities, less current portion 1,562 2,093 Total lease liabilities $ 49,141 $ 43,453 Operating and finance leases Weighted average remaining lease term (years): Operating leases 16.6 12.4 Finance lease 3.7 4.7 Weighted average discount rate Operating leases 6.0 3.3 Finance lease 5.3 5.3 Supplemental cash flow information related to our leases were as follows (in thousands): Schedule of supplemental cash flow information related to leases Fiscal Year Ended April 30, 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 4,069 $ 2,376 $ 2,972 Operating cash flows from finance leases 125 47 5 Financing cash flows from finance leases 505 162 93 Non-cash transactions: Right-of-use assets obtained upon operating lease modifications and reassessments, net $ 9,267 $ 4,554 $ – Right-of-use assets obtained in exchange for operating lease obligations $ – $ 16,093 $ – Decapitalization of right-of-use assets upon impairment $ 89 $ – $ – Property and equipment obtained in exchange for finance lease obligation $ – $ 2,760 $ – As of April 30, 2023, the maturities of our lease liabilities, which includes those derived from lease renewal options that we considered it reasonably certain that we would exercise, were as follows (in thousands): Schedule of maturities of operating lease liabilities Fiscal Year Ending April 30, Operating Leases Finance Lease Total 2024 $ 4,140 $ 629 $ 4,769 2025 4,060 629 4,689 2026 4,167 629 4,796 2027 4,199 419 4,618 2028 4,036 – 4,036 Thereafter 56,418 – 56,418 Total lease payments $ 77,020 $ 2,306 $ 79,326 Less: imputed interest (29,972 ) (213 ) (30,185 ) Total lease liabilities $ 47,048 $ 2,093 $ 49,141

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Apr. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Note 5 – Stockholders’ Equity Series E Preferred Stock Redemption and Dividends During the fourth quarter of fiscal 2021 and prior to the redemption discussed below, holders of our 10.50% Series E Convertible Preferred Stock (the “Series E Preferred Stock”) converted an aggregate of 28,168 33,514 21.00 On April 12, 2021 (the “Redemption Date”), we redeemed all then current remaining outstanding shares of our Series E Preferred Stock at a per share price equal to the $ 25.00 3.4 million Holders of our Series E Preferred Stock were entitled to receive cumulative dividends at the rate of 10.50% per annum based on the liquidation preference of $ 25.00 2.625 0.08021 4.5 million No Sale of Common Stock During the third quarter of fiscal 2021, we completed an underwritten public offering pursuant to which we sold 3,833,335 9.00 500,000 34.5 million 2.4 million During the fiscal years ended April 30, 2023 and 2022, we had no Shares of Common Stock Authorized and Reserved for Future Issuance As of April 30, 2023, 62,691,885 Our common stock outstanding as of April 30, 2023 excluded the following shares of common stock reserved for future issuance (in thousands): Schedule of common stock reserved for future issuance Shares Stock Incentive Plans 8,338 Employee Stock Purchase Plan 963 Conversion of Convertible Notes 6,776 Total common stock reserved for future issuance 16,077

Equity Compensation Plans

Equity Compensation Plans	12 Months Ended
	Apr. 30, 2023
Share-Based Payment Arrangement [Abstract]
Equity Compensation Plans	Note 6 – Equity Compensation Plans Stock Incentive Plans The Avid Bioservices, Inc. 2018 Omnibus Incentive Plan (the “2018 Plan”) is a stockholder-approved plan, which provides, among other things, the ability for us to grant stock options, restricted stock units, performance stock units and other forms of stock-based awards. The 2018 Plan replaced our 2009, 2010 and 2011 Stock Incentive Plans (the “Prior Plans”). However, any awards outstanding under the Prior Plans as of the 2018 Plan’s effective date continue to remain subject to and be paid under the applicable Prior Plan, and any shares subject to outstanding awards under the Prior Plans that subsequently expire, terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under the 2018 Plan. In October 2021, our stockholders approved an amendment to the 2018 Plan to increase the number of authorized shares reserved for issuance under the 2018 plan by 3.4 million The 2018 Plan and the Prior Plans are collectively referred to as the “Stock Plans”. As of April 30, 2023, we had an aggregate of 8,337,807 3,926,550 4,411,257 Stock Options We ceased granting stock options during fiscal 2022. Stock options previously granted under our Stock Plans were granted at an exercise price not less than the fair market value of our common stock on the date of grant. Stock options granted to employees generally vest over a four-year period from the date of grant and stock options granted to non-employee directors generally vest over a period of one to three years from the date of grant. Stock options granted under the 2018 Plan have a contractual term of seven years; however, the maximum contractual term of any stock option granted under the Stock Plans is ten years. The estimated fair value of stock options is measured at the grant date, using a fair value-based method, such as a Black-Scholes option valuation model, and is amortized as stock-based compensation expense on a straight-line basis over the requisite service period of the award, which is generally the vesting period. The use of a valuation model requires us to make certain estimates and assumptions with respect to selected model inputs. The expected volatility is based on the daily historical volatility of our common stock covering the estimated expected term. The expected term of options granted reflects actual historical exercise activity and assumptions regarding future exercise activity of unexercised, outstanding options. The risk-free interest rate is based on U.S. Treasury notes with terms within the contractual life of the option at the time of grant. The expected dividend yield assumption is based on our expectation of future dividend payouts. We have never declared or paid any cash dividends on our common stock and currently do not anticipate paying such cash dividends. There were no Schedule of fair value assumptions for options Fiscal Year Ended April 30, 2022 2021 Risk-free interest rate 0.86 0.32 Expected life (in years) 4.37 4.69 Expected volatility 68.64 81.42 Expected dividend yield – – The following summarizes our stock option transaction activity for the fiscal year ended April 30, 2023: Schedule of stock option activity Stock Options (in thousands) Grant Date Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (1) (in thousands) Outstanding at May 1, 2022 2,505 $ 6.88 Granted – – Exercised (366 ) $ 7.06 Canceled or expired (60 ) $ 9.89 Outstanding at April 30, 2023 2,079 $ 6.76 3.69 $ 23,654 Vested and expected to vest 2,079 $ 6.76 3.69 $ 23,654 Exercisable at April 30, 2023 1,595 $ 6.52 3.59 $ 18,447 ______________ (1) Aggregate intrinsic value represents the difference between the exercise price of an option and the closing market price of our common stock on April 28, 2023 (the last trading day of fiscal year 2023), which was $18.05 per share. The weighted-average grant date fair value of stock options granted during the fiscal years ended April 30, 2022 and 2021 was $ 13.09 4.74 no The aggregate intrinsic value of stock options exercised during the fiscal years ended April 30, 2023, 2022 and 2021 was $ 3.5 million 8.1 million 3.9 million 2.6 million 2.7 million 3.6 million We issue shares of common stock that are reserved for issuance under the Stock Plans upon the exercise of stock options, and we do not expect to repurchase shares of common stock from any source to satisfy our obligations under our compensation plans. As of April 30, 2023, the total estimated unrecognized compensation cost related to non-vested stock options was $1.3 million. This cost is expected to be recognized over a weighted average vesting period of 0.99 Restricted Stock A restricted stock unit (“RSU”) represents the right to receive one share of our common stock upon the vesting of such unit. RSUs granted to employees generally vest over a four-year period from the date of grant and RSUs granted to non-employee directors generally vest over a period of one to three years from the date of grant. The estimated fair value of RSUs is based on the closing market value of our common stock on the date of grant and is amortized as stock-based compensation expense on a straight-line basis over the period of vesting. The following summarizes our RSUs transaction activity for the fiscal year ended April 30, 2023: Schedule of RSU activity Shares (in thousands) Weighted Average Grant Date Fair Value Outstanding at May 1, 2022 642 $ 14.89 Granted 780 $ 17.63 Vested (366 ) $ 15.09 Forfeited (50 ) $ 17.32 Outstanding at April 30, 2023 1,006 $ 16.83 The weighted-average grant date fair value of RSUs granted during the fiscal years ended April 30, 2023, 2022 and 2021 was $ 17.63 25.20 7.29 The total fair value of RSUs vested during the fiscal years ended April 30, 2023, 2022 and 2021 was $ 6.3 million 5.5 million 0.7 million As of April 30, 2023, the total estimated unrecognized compensation cost related to non-vested RSUs was $ 15.4 million 2.53 Performance Stock Units The Compensation Committee of the Board of Directors grants PSUs to our executives. The PSUs are subject to annual vesting over three consecutive fiscal year performance periods with the first one-third vesting on April 30 of the year following the grant date, and each successive one-third vesting on April 30 of the following two years respectively (each a “Performance Period”). Each PSU that vests represent the right to receive one share of our common stock. The number of shares that will vest for each Performance Period, if any, is based upon the attainment of certain predetermined financial metrics for each such Performance Period. Depending on the actual financial metrics achieved relative to the target financial metrics for such Performance Periods, the number of PSUs issued could range from 0% to 200% of the target amount. The number of granted shares included in the table below is based on a maximum 200% achievement of each financial metric during each Performance Period (the “Maximum Performance Target”). If a financial metric is achieved at a rate below the Maximum Performance Target, or is not achieved, the corresponding portion of the PSUs that do not vest are forfeited. The following summarizes our PSUs transaction activity for the fiscal year ended April 30, 2023: Schedule of PSU activity Shares (in thousands) Weighted Average Grant Date Fair Value Outstanding at May 1, 2022 233 $ 25.31 Granted 608 $ 18.09 Vested (161 ) $ 20.75 Forfeited (158 ) $ 20.69 Outstanding at April 30, 2023 522 $ 19.70 The weighted-average grant date fair value of PSUs granted during the fiscal years ended April 30, 2023 and 2022, was $ 18.09 25.36 no The total fair value of PSUs vested during the fiscal years ended April 30, 2023 and 2022 was $ 3.3 million 2.1 million No As of April 30, 2023, there was $ 10.3 million 1.39 Employee Stock Purchase Plan The Avid Bioservices, Inc. 2010 Employee Stock Purchase Plan (the “ESPP”) is a stockholder-approved plan under which employees can purchase shares of our common stock, based on a percentage of their compensation, subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the first trading day of the six-month offering period or on the last trading day of the six-month offering period. Offering Periods commence on or about the first day of January and July of each year. During the fiscal years ended April 30, 2023, 2022 and 2021, a total of 68,646 44,364 72,409 12.22 14.50 5.84 The fair value of the shares purchased under the ESPP was determined using a Black-Scholes option valuation model (see explanation of valuation model inputs above under “Stock Options”) and is recognized as expense on a straight-line basis over the requisite service period (or six-month offering period). The weighted average grant date fair value of purchase rights under the ESPP during fiscal years ended April 30, 2023, 2022 and 2021 was $ 4.93 8.62 3.17 Schedule of ESPP Fair value assumptions Fiscal Year Ended April 30, 2023 2022 2021 Risk-free interest rate 3.76 0.15 0.14 Expected life (in years) 0.50 0.50 0.50 Expected volatility 68.60 59.91 75.50 Expected dividend yield – – – Stock-based Compensation Expense Stock-based compensation expense included in our consolidated statements of income and comprehensive income was comprised of the following (in thousands): Schedule of share-based compensation expense Fiscal Year Ended April 30, 2023 2022 2021 Cost of revenues $ 3,876 $ 2,540 $ 1,404 Selling, general and administrative expense 7,102 4,840 2,450 Total $ 10,978 $ 7,380 $ 3,854

Income Taxes

Income Taxes	12 Months Ended
	Apr. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 – Income Taxes Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. At April 30, 2023, management assessed the realizability of deferred tax assets and evaluated the need for a valuation allowance for deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740 wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of our deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more-likely-than-not that the asset will not be realized. In assessing the realization of our deferred tax assets, management considers all available evidence, both positive and negative. Management’s evaluation placed significant emphasis on guidance in ASC 740, which states that “a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome.” In fiscal 2022, we transitioned from a cumulative loss in recent years to cumulative income. This transition coupled with additional positive evidence enabled us to fully release our valuation allowance as of April 30, 2022. We maintained the same position that our deferred tax assets did not require a valuation allowance as of April 30, 2023. The valuation allowance did no 11.3 We are subject to taxation in the United States and various states jurisdictions. We have not been notified that we are under audit by the IRS or any state taxing authorities and our federal and state returns from April 30, 2020 and April 30, 2019, respectively, remain open for examination. Due to the presence of net operating loss (“NOL”) carryforwards the tax authorities can also examine years prior to the standard statute of limitations. At April 30, 2023, we had federal NOL carry forwards of approximately $ 442.4 million 294.7 million 0.9 million Additionally, the future utilization of our NOL carry forwards to offset future taxable income may be subject to an annual limitation, pursuant to Internal Revenue Code Section 382, as a result of ownership changes. A Section 382 analysis has been completed through April 30, 2022, and it was determined that no significant change in ownership had occurred. However, ownership changes occurring subsequent to April 30, 2022 may impact the utilization of NOL carry forwards and other tax attributes in future periods. At April 30, 2023, we had $ 5.8 million 1.5 million The provision for income taxes on our net income before income taxes for the fiscal years ended April 30, 2023, 2022 and 2021 is comprised of the following (in thousands): Schedule of provision for income taxes 2023 2022 2021 (as restated) Federal income taxes at statutory rate $ 334 $ 2,659 $ 2,355 State income taxes, net of valuation allowance 276 605 – Expiration and adjustments of deferred tax assets – – 451 Change in federal valuation allowance – (122,703 ) 2,450 Stock-based compensation including 162M limitations 615 (1,153 ) (240 ) Research and development credits – – (4,958 ) Adjustment for federal benefit of state – 5,326 – Permanent differences 66 425 4 Other, net 40 (170 ) (62 ) Income tax expense (benefit) $ 1,331 $ (115,011 ) $ – Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant components of our deferred tax assets and deferred tax liabilities at April 30, 2023 and 2022 are as follows (in thousands): Schedule of deferred tax assets and deferred tax liabilities 2023 2022 (as restated) Net operating losses $ 112,194 $ 99,710 Research and development credits 5,569 5,550 Stock-based compensation 2,589 2,710 Deferred revenue 2,420 5,494 Lease liabilities 12,742 11,107 Accrued liabilities 2,360 785 Accrued compensation 1,781 1,705 Total deferred tax assets 139,655 127,061 Less valuation allowance – – Total deferred tax assets, net of valuation allowance 139,655 127,061 Deferred tax liabilities: Fixed assets (14,320 ) (1,972 ) ROU assets (11,584 ) (10,007 ) Total deferred tax liabilities (25,904 ) (11,979 ) Net deferred tax assets $ 113,751 $ 115,082 In accordance with ASC 740, we are required to recognize the impact of an uncertain tax position in the consolidated financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained upon examination by the tax authorities. Unrecognized tax positions at April 30, 2023 and 2022 are as follows (in thousands): Schedule of unrecognized tax positions 2023 2022 Unrecognized tax positions, beginning of year $ 5,133 $ 1,600 Gross (decrease) increase – prior period tax positions (1,693 ) 3,533 Unrecognized tax positions, end of year $ 3,440 $ 5,133 If recognized, the unrecognized tax positions will impact our income tax benefit or effective tax rate. We do not expect any significant increases or decreases to our unrecognized tax positions within the next 12 months. It is our policy to recognize interest and penalties related to income tax matters in interest expense and other income (expense), net, respectively, in our consolidated statements of income and comprehensive income. For the fiscal years ended April 30, 2023 and 2021, we did not incur any interest or penalties. For the fiscal year ended April 30, 2022, we recognized an immaterial amount of interest and penalties.

Net Income Per Common Share

Net Income Per Common Share	12 Months Ended
	Apr. 30, 2023
Net income per share attributable to common stockholders:
Net Income Per Common Share	Note 8 – Net Income Per Common Share Basic net income per common share is computed by dividing our net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing our net income attributable to common stockholders by the sum of the weighted average number of shares of common stock outstanding during the period plus the potential dilutive effects of stock options, unvested RSUs and PSUs, shares of common stock expected to be issued under our ESPP, 2026 Notes and Series E Preferred Stock outstanding during the period. Net income attributable to common stockholders represents our net income less Series E Preferred Stock accumulated dividends and the impact of Series E Preferred Stock redemption. The potential dilutive effect of stock options, unvested RSUs and PSUs, and shares of common stock expected to be issued under our ESPP during the period are calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. The potential dilutive effect of our 2026 Notes and Series E Preferred Stock outstanding during the period are calculated using the if-converted method assuming the conversion of our 2026 Notes and Series E Preferred Stock as of the earliest period reported or at the date of issuance, if later, but are excluded if their effect is anti-dilutive. A reconciliation of the numerators and the denominators of the basic and dilutive net income per common share computations are as follows (in thousands, except per share amounts): Schedule of earnings per share, basic and diluted Fiscal Year Ended April 30, 2023 2022 2021 (as restated) Numerator Net income $ 259 $ 127,672 $ 11,212 Series E preferred stock accumulated dividends – – (4,455 ) Impact of Series E preferred stock redemption – – (3,439 ) Net income attributable to common stockholders, basic $ 259 $ 127,672 $ 3,318 Add interest expense on 2026 Notes, net of tax – 1,954 – Net income attributable to common stockholders, diluted $ 259 $ 129,626 $ 3,318 Denominator Weighted average basic common shares outstanding 62,268 61,484 58,222 Effect of dilutive securities: Stock options 1,248 1,830 909 RSUs, PSUs and ESPP 266 384 295 2026 Notes – 6,776 – Weighted average dilutive common shares outstanding 63,782 70,474 59,426 Net income per share attributable to common stockholders: Basic $ 0.00 $ 2.08 $ 0.06 Diluted $ 0.00 $ 1.84 $ 0.06 The following table presents the potential dilutive securities excluded from the calculation of diluted net income (loss) per common share for the periods presented as the effect of their inclusion would have been anti-dilutive (in thousands): Schedule of antidilutive shares Fiscal Year Ended April 30, 2023 2022 2021 Stock options 46 43 829 RSUs, PSUs and ESPP 253 9 – 2026 Notes 6,776 – 928 Series E Preferred Stock – – 1,864 Total 7,075 52 3,621

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Apr. 30, 2023
Retirement Benefits [Abstract]
Employee Benefit Plan	Note 9 – Employee Benefit Plan We maintain a 401(k) Plan pursuant to section 401(k) of the Internal Revenue Code that allows participating employees to defer a portion of their compensation on a tax deferred basis up to the maximum amount permitted by the Internal Revenue Code. We are not required to make matching contributions under the 401(k) Plan. However, we match 50% of employee contributions of up to 6% of their annual eligible compensation. Total expense recognized by us for matching contributions to the 401(k) Plan for the fiscal years ended April 30, 2023, 2022 and 2021 was $ 0.9 million 0.6 million 0.5 million

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Apr. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 – Commitments and Contingencies In the ordinary course of business, we are at times subject to various legal proceedings and disputes. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions, if any, are reviewed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. We currently are not a party to legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated financial condition or results of operations. Humanigen Arbitration On December 17, 2021, we filed a Demand for Arbitration claiming more than $20.5 million in damages against Humanigen, Inc. (“Humanigen”) with the American Arbitration Association (“AAA”) entitled, Avid Bioservices, Inc. v. Humanigen, Inc. (AAA Case No. 01-21-0018-0523). The Demand contains three claims for: (1) breach of contract concerning the process development and manufacturing master services agreement (“MSA”); (2) anticipatory breach of contract concerning the capacity expansion and contribution/commitment letter (“Letter Agreement”); and (3) trade libel and commercial disparagement. On January 6, 2022, Humanigen filed an Answer to our Demand, denying the allegations and asserting affirmative defenses. On July 1, 2022, Humanigen filed its counterclaims against us in the form of a complaint in the Orange County Superior Court (Case No. 30-2022-01268184) alleging three claims for (1) breach of the MSA seeking return or reimbursement of the amounts Humanigen paid us before cancelling the MSA, (2) declaratory relief that Humanigen has no remaining obligations under the Letter Agreement, and (3) unfair business practices. On July 19, 2022, we filed a motion with the state court to compel all claims by Humanigen against us to arbitration before the AAA. On October 17, 2022, the state court granted our motion to compel all of Humanigen’s claims against us to arbitration and denied Humanigen’s motion to stay the arbitration. As a result of the court having granted our motion, on November 3, 2022, Humanigen filed its Demand for Arbitration realleging the breach of the MSA and unfair business practices claims which it had initially filed in state court. On November 10, 2022, we filed an Answer to Humanigen’s Demand, denying the allegations and asserting affirmative defenses. On February 21, 2023, we entered into a Confidential Settlement and Mutual Releases Agreement with Humanigen resolving the arbitration proceeding and all disputes between the parties.

Subsequent Events

Subsequent Events	12 Months Ended
	Apr. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 11 – Subsequent Events Acceleration of Convertible Senior Notes Due 2026 As described in Note 1, on February 29, 2024, as a result of the Event of Default, a holder of at least 25% aggregate principal amount of 2026 Notes declared 100% of the principal amount of, and accrued and unpaid interest on, the 2026 Notes to be due and payable immediately. Sale and Issuance of Convertible Senior Notes Due 2029 On March 12, 2024, we completed a private offering (the “Offering”) of $160.0 million aggregate principal amount of 7.00% convertible senior notes due 2029 (the “2029 Notes”) to qualified institutional buyers pursuant to Section 4(a)(2) of the Securities Act. We received net proceeds from the Offering of approximately $153.5 million, after deducting placement agent’s commissions and other debt issuance related expenses of approximately $6.5 million. Subsequent to the closing of the Offering, during March 2024, we used approximately $146.1 million of the net proceeds to (i) repurchase for cash, $141.0 million aggregate principal amount of the 2026 Notes (Note 3) in privately negotiated transactions with certain holders of the 2026 Notes plus accrued and unpaid interest of $2.3 million, and (ii) repay in full, the remaining outstanding 2026 Notes balance by depositing the required payoff amount of $2.8 million, representing principal and accrued and unpaid interest, with the trustee under the 2026 Notes Indenture, following which no 2026 Notes remained outstanding. The 2029 Notes are senior unsecured obligations and accrue interest at a rate of 7.00% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2024. The 2029 Notes mature on March 1, 2029, unless earlier repurchased by us or converted at the option of the holders. The 2029 Notes are convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election in the manner and subject to the terms and conditions provided in the indenture (the “2029 Notes Indenture”) governing the 2029 Notes. The initial conversion rate for the 2029 Notes is approximately 101.1250 shares of our common stock per $1,000 principal amount, which represents an initial conversion price of approximately $9.89 per share of our common stock. The conversion rate is subject to adjustments upon the occurrence of certain events in accordance with the terms of the 2029 Notes Indenture. In addition, following certain corporate events that occur prior to the maturity date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert their 2029 Notes in connection with such a fundamental change, as defined in the 2029 Notes Indenture. Holders of the 2029 Notes may convert their 2029 Notes at their option at any time prior to the close of business on the business day immediately preceding September 1, 2028, only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending July 31, 2024 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price for the 2029 Notes on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the 2029 Notes Indenture) per $1,000 principal amount of the 2029 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events as described in the 2029 Notes Indenture. On or after September 1, 2028 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders at their option may convert all or any portion of their 2029 Notes at any time, regardless of the foregoing circumstances. We may not redeem the 2029 Notes prior to the March 1, 2029 maturity date. If we undergo a fundamental change (as defined in the 2029 Notes Indenture), holders may require us to repurchase for cash all or any portion of their 2029 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2029 Notes to be repurchased, plus accrued and unpaid interest to, but excluding the fundamental change repurchase date. The 2029 Notes Indenture includes customary terms and covenants, including that upon certain events of default occurring and continuing, if we fail to comply with any of our other agreements contained in the 2029 Notes or the 2029 Notes Indenture for 60 days after receipt of written notice of such failure from the trustee or the holders of at least 25% in aggregate principal amount of the outstanding 2029 Notes may declare the entire principal of all the 2029 Notes plus accrued and unpaid interest to be immediately due and payable. Capped Call Transactions During March 2024, in connection with our repurchase and payoff of the remaining balance of the 2026 Notes, as further described above, we entered into transactions to unwind all of our Capped Calls (Note 3). As a result, we received $1.3 million in net proceeds from the unwinding of the Capped Calls. Revolving Credit Facility On March 12, 2024, we entered into Amendment No. 2 to the Credit Agreement (Note 3) which, among other things, (i) waives the events of default under the Credit Agreement as a result of the acceleration of the 2026 Notes, (ii) permits the issuance of the 2029 Notes and the repayment of the 2026 Notes and (iii) adjusts certain financial covenant in the Credit Agreement.

Restatement of Previously Repor

Restatement of Previously Reported Fiscal 2023 Interim Financial Statements (Unaudited)	12 Months Ended
	Apr. 30, 2023
Equity [Abstract]
Restatement of Previously Reported Fiscal 2023 Interim Financial Statements (Unaudited)	Note 12 – Restatement of Previously Reported Fiscal 2023 Interim Financial Statements (Unaudited) The impact from the restatement described in Note 1 on the line items within our unaudited condensed consolidated financial statements as of and for the three and nine months ended January 31, 2023 previously filed in our Quarterly Report on Form 10-Q for the quarter ended January 31, 2023 are as follows (in thousands, except par value and per share information): The impact on the line items within our unaudited condensed consolidated financial statements as of and for the three and nine months ended January 31, 2023 previously filed in our Quarterly Report on Form 10-Q for the quarter ended January 31, 2023 are as follows (in thousands, except par value and per share information): Schedule of consolidated balance sheet As of January 31, 2023 Condensed Consolidated Balance Sheet (as reported) (adjustments) (as restated) ASSETS Current assets: Cash and cash equivalents $ 59,916 $ – $ 59,916 Accounts receivable, net 14,826 – 14,826 Contract assets 10,388 – 10,388 Inventory 45,102 – 45,102 Prepaid expenses and other current assets 2,111 – 2,111 Total current assets 132,343 – 132,343 Property and equipment, net 164,292 118 164,410 Operating lease right-of-use assets 34,463 – 34,463 Deferred tax assets 114,580 237 114,817 Other assets 4,402 – 4,402 Restricted cash 350 – 350 Total assets $ 450,430 $ 355 $ 450,785 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 36,392 $ – $ 36,392 Accrued compensation and benefits 8,400 – 8,400 Contract liabilities 37,750 – 37,750 Convertible senior notes, net – 140,359 140,359 Current portion of operating lease liabilities 3,024 – 3,024 Other current liabilities 1,753 630 2,383 Total current liabilities 87,319 140,989 228,308 Convertible senior notes, net 140,359 (140,359 ) – Operating lease liabilities, less current portion 35,659 – 35,659 Finance lease liabilities, less current portion 1,698 – 1,698 Total liabilities 265,035 630 265,665 Commitments and contingencies – – – Stockholders’ equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates – – – Common stock, $0.001 par value; 150,000 shares authorized; 62,523 and 61,807 shares issued and outstanding at respective dates 62 – 62 Additional paid-in capital 615,841 – 615,841 Accumulated deficit (430,508 ) (275 ) (430,783 ) Total stockholders’ equity 185,395 (275 ) 185,120 Total liabilities and stockholders’ equity $ 450,430 $ 355 $ 450,785 Schedule of consolidated statement of income and comprehensive income Three Months Ended January 31, 2023 Condensed Consolidated Statement of Income (Loss) and Comprehensive Income (Loss) (as reported) (adjustments) (as restated) Revenues $ 38,018 $ – $ 38,018 Cost of revenues 28,193 – 28,193 Gross profit 9,825 – 9,825 Operating expenses: Selling, general and administrative 7,107 – 7,107 Total operating expenses 7,107 – 7,107 Operating income 2,718 – 2,718 Interest expense (620 ) (16 ) (636 ) Other income (expense), net 432 – 432 Net income before income taxes 2,530 (16 ) 2,514 Income tax expense 2,069 692 2,761 Net income (loss) $ 461 $ (708 ) $ (247 ) Comprehensive income (loss) $ 461 $ (708 ) $ (247 ) Net income (loss) per share: Basic $ 0.01 $ (0.01 ) $ (0.00 ) Diluted $ 0.01 $ (0.01 ) $ (0.00 ) Weighted average common shares outstanding: Basic 62,388 – 62,388 Diluted 63,726 5,438 69,164 Nine Months Ended January 31, 2023 Condensed Consolidated Statement of Income and Comprehensive Income (as reported) (adjustments) (as restated) Revenues $ 109,467 $ – $ 109,467 Cost of revenues 86,378 – 86,378 Gross profit 23,089 – 23,089 Operating expenses: Selling, general and administrative 20,320 – 20,320 Total operating expenses 20,320 – 20,320 Operating income 2,769 – 2,769 Interest expense (1,841 ) (513 ) (2,354 ) Other income (expense), net 627 – 627 Net income before income taxes 1,555 (513 ) 1,042 Income tax expense 686 (238 ) 448 Net income $ 869 $ (275 ) $ 594 Comprehensive income $ 869 $ (275 ) $ 594 Net income per share: Basic $ 0.01 $ – $ 0.01 Diluted $ 0.01 $ – $ 0.01 Weighted average common shares outstanding: Basic 62,166 – 62,166 Diluted 63,634 – 63,634 Schedule of condensed consolidated statement of stockholders’ equity Three Months Ended January 31, 2023 Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at October 31, 2022 $ (430,969 ) $ 181,195 $ 433 $ (430,536 ) $ 181,628 Common stock issued under equity compensation plans – 995 – – 995 Stock-based compensation expense – 2,744 – – 2,744 Net income (loss) 461 461 (708 ) (247 ) (247 ) Balances at January 31, 2023 $ (430,508 ) $ 185,395 $ (275 ) $ (430,783 ) $ 185,120 Nine Months Ended January 31, 2023 Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at April 30, 2022 $ (431,377 ) $ 174,526 $ – $ (431,377 ) $ 174,526 Common stock issued under equity compensation plans – 2,573 – – 2,573 Stock-based compensation expense – 7,427 – – 7,427 Net income 869 869 (275 ) 594 594 Balances at January 31, 2023 $ (430,508 ) $ 185,395 $ (275 ) $ (430,783 ) $ 185,120 Schedule of consolidated statement of cash flows Nine Months Ended January 31, 2023 Condensed Consolidated Statement of Cash Flows (as reported) (adjustments) (as restated) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 869 $ (275 ) $ 594 Adjustments to reconcile net income to net cash used in operating activities: Stock-based compensation 7,427 – 7,427 Depreciation and amortization 5,326 – 5,326 Amortization of debt issuance costs 782 – 782 Deferred income taxes 502 (237 ) 265 Loss on disposal of property and equipment 82 – 82 Changes in operating assets and liabilities: Accounts receivable, net 5,721 – 5,721 Contract assets (5,019 ) – (5,019 ) Inventory (19,040 ) – (19,040 ) Prepaid expenses and other assets (7 ) – (7 ) Accounts payable 2,904 – 2,904 Accrued compensation and benefits (18 ) – (18 ) Contract liabilities (16,048 ) – (16,048 ) Other accrued expenses and liabilities 833 331 1,164 Net cash used in operating activities (15,686 ) (181 ) (15,867 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (52,761 ) 181 (52,580 ) Net cash used in investing activities (52,761 ) 181 (52,580 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock under equity compensation plans 2,573 – 2,573 Principal payments on finance lease (376 ) – (376 ) Net cash provided by financing activities 2,197 – 2,197 Net decrease in cash, cash equivalents and restricted cash (66,250 ) – (66,250 ) Cash, cash equivalents and restricted cash, beginning of period 126,516 – 126,516 Cash, cash equivalents and restricted cash, end of period $ 60,266 – $ 60,266 Supplemental disclosures of cash flow information: Cash paid for interest $ 224 $ 268 $ 492 Cash paid for income taxes $ 220 $ – $ 220 Supplemental disclosures of investing non-cash activities: Unpaid purchases of property and equipment $ 23,984 $ 299 $ 24,283 The impact from the restatement on the line items within our unaudited condensed consolidated financial statements as of and for the three and six months ended October 31, 2022 previously filed in our Quarterly Report on Form 10-Q for the quarter ended October 31, 2022 are as follows (in thousands, except par value and per share information): Schedule of consolidated balance sheet As of October 31, 2022 Condensed Consolidated Balance Sheet (as reported) (adjustments) (as restated) ASSETS Current assets: Cash and cash equivalents $ 77,292 $ – $ 77,292 Accounts receivable, net 20,580 – 20,580 Contract assets 6,528 – 6,528 Inventory 39,061 – 39,061 Prepaid expenses and other current assets 2,480 – 2,480 Total current assets 145,941 – 145,941 Property and equipment, net 139,386 (49 ) 139,337 Operating lease right-of-use assets 35,373 – 35,373 Deferred tax assets 116,647 930 117,577 Other assets 4,153 – 4,153 Restricted cash 350 – 350 Total assets $ 441,850 $ 881 $ 442,731 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 23,328 $ – $ 23,328 Accrued compensation and benefits 6,007 – 6,007 Contract liabilities 48,446 – 48,446 Convertible senior notes, net – 140,097 140,097 Current portion of operating lease liabilities 3,111 – 3,111 Other current liabilities 1,485 448 1,933 Total current liabilities 82,377 140,545 222,922 Convertible senior notes, net 140,097 (140,097 ) – Operating lease liabilities, less current portion 36,350 – 36,350 Finance lease liabilities, less current portion 1,831 – 1,831 Total liabilities 260,655 448 261,103 Commitments and contingencies – – – Stockholders’ equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates – – – Common stock, $0.001 par value; 150,000 shares authorized; 62,308 and 61,807 shares issued and outstanding at respective dates 62 – 62 Additional paid-in capital 612,102 – 612,102 Accumulated deficit (430,969 ) 433 (430,536 ) Total stockholders’ equity 181,195 433 181,628 Total liabilities and stockholders’ equity $ 441,850 $ 881 $ 442,731 Schedule of consolidated statement of income and comprehensive income Three Months Ended October 31, 2022 Condensed Consolidated Statement of Loss and Comprehensive Loss (as reported) (adjustments) (as restated) Revenues $ 34,757 $ – $ 34,757 Cost of revenues 30,610 – 30,610 Gross profit 4,147 – 4,147 Operating expenses: Selling, general and administrative 6,831 – 6,831 Total operating expenses 6,831 – 6,831 Operating loss (2,684 ) – (2,684 ) Interest expense (703 ) (174 ) (877 ) Other income, net 145 – 145 Net loss before income taxes (3,242 ) (174 ) (3,416 ) Income tax benefit (2,086 ) (810 ) (2,896 ) Net loss $ (1,156 ) $ 636 $ (520 ) Comprehensive loss $ (1,156 ) $ 636 $ (520 ) Net loss per share: Basic $ (0.02 ) $ 0.01 $ (0.01 ) Diluted $ (0.02 ) $ 0.01 $ (0.01 ) Weighted average common shares outstanding: Basic 62,204 – 62,204 Diluted 62,204 – 62,204 Six Months Ended October 31, 2022 Condensed Consolidated Statement of Income and Comprehensive Income (as reported) (adjustments) (as restated) Revenues $ 71,449 $ – $ 71,449 Cost of revenues 58,185 – 58,185 Gross profit 13,264 – 13,264 Operating expenses: Selling, general and administrative 13,213 – 13,213 Total operating expenses 13,213 – 13,213 Operating income 51 – 51 Interest expense (1,221 ) (497 ) (1,718 ) Other income, net 195 – 195 Net loss before income taxes (975 ) (497 ) (1,472 ) Income tax benefit (1,383 ) (930 ) (2,313 ) Net income $ 408 $ 433 $ 841 Comprehensive income $ 408 $ 433 $ 841 Net income per share: Basic $ 0.01 $ – $ 0.01 Diluted $ 0.01 $ (0.01 ) $ (0.00 ) Weighted average common shares outstanding: Basic 62,054 – 62,054 Diluted 63,574 6,776 70,350 Schedule of condensed consolidated statement of stockholders’ equity Three Months Ended October 31, 2022 Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at July 31, 2022 $ (429,813 ) $ 178,999 $ (203 ) $ (430,016 ) $ 178,796 Common stock issued under equity compensation plans – 566 – – 566 Stock-based compensation expense – 2,786 – – 2,786 Net loss (1,156 ) (1,156 ) 636 (520 ) (520 ) Balances at October 31, 2022 $ (430,969 ) $ 181,195 $ 433 $ (430,536 ) $ 181,628 Six Months Ended October 31, 2022 Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at April 30, 2022 $ (431,377 ) $ 174,526 $ – $ (431,377 ) $ 174,526 Common stock issued under equity compensation plans – 1,578 – – 1,578 Stock-based compensation expense – 4,683 – – 4,683 Net income 408 408 433 841 841 Balances at October 31, 2022 $ (430,969 ) $ 181,195 $ 433 $ (430,536 ) $ 181,628 Schedule of consolidated statement of cash flows Six Months Ended October 31, 2022 Condensed Consolidated Statement of Cash Flows (as reported) (adjustments) (as restated) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 408 $ 433 $ 841 Adjustments to reconcile net income to net cash used in operating activities: Stock-based compensation 4,683 – 4,683 Depreciation and amortization 3,409 – 3,409 Amortization of debt issuance costs 520 – 520 Deferred income taxes (1,565 ) (930 ) (2,495 ) Loss on disposal of property and equipment 70 – 70 Changes in operating assets and liabilities: Accounts receivable, net (33 ) – (33 ) Contract assets (1,159 ) – (1,159 ) Inventory (12,999 ) – (12,999 ) Prepaid expenses and other assets (127 ) – (127 ) Accounts payable 5,346 – 5,346 Accrued compensation and benefits (2,411 ) – (2,411 ) Contract liabilities (5,352 ) – (5,352 ) Other accrued expenses and liabilities 439 342 781 Net cash used in operating activities (8,771 ) (155 ) (8,926 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (41,432 ) 155 (41,277 ) Net cash used in investing activities (41,432 ) 155 (41,277 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock under equity compensation plans 1,578 – 1,578 Principal payments on finance leases (249 ) – (249 ) Net cash provided by financing activities 1,329 – 1,329 Net decrease in cash, cash equivalents and restricted cash (48,874 ) – (48,874 ) Cash, cash equivalents and restricted cash, beginning of period 126,516 – 126,516 Cash, cash equivalents and restricted cash, end of period $ 77,642 – $ 77,642 Supplemental disclosures of cash flow information: Cash paid for interest $ 438 $ 312 $ 750 Cash paid for income taxes $ 220 $ – $ 220 Supplemental disclosures of non-cash activities: Unpaid purchases of property and equipment $ 8,478 $ 106 $ 8,584 In connection with the restatement of the 2023 fiscal period we did correct certain errors for the three-month period ended July 31, 2022 that when aggregated are not material to any of our previously issued annual or interim financial statements. The effects of the correction of these immaterial errors on the line items within our unaudited condensed consolidated financial statements as of and for the three months ended July 31, 2022 previously filed in our Quarterly Report on Form 10-Q for the quarter ended July 31, 2022 are as follows (in thousands, except par value and per share information): Schedule of consolidated balance sheet As of July 31, 2022 Condensed Consolidated Balance Sheet (as reported) (corrections) (as corrected) ASSETS Current assets: Cash and cash equivalents $ 115,137 $ – $ 115,137 Accounts receivable, net 25,945 – 25,945 Contract assets 7,078 – 7,078 Inventory 30,354 – 30,354 Prepaid expenses 2,121 – 2,121 Total current assets 180,635 – 180,635 Property and equipment, net 114,929 (55 ) 114,874 Operating lease right-of-use assets 36,093 – 36,093 Deferred tax assets 114,472 48 114,520 Other assets 4,740 – 4,740 Restricted cash 350 – 350 Total assets $ 451,219 $ (7 ) $ 451,212 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 30,461 $ – $ 30,461 Accrued compensation and benefits 5,300 – 5,300 Contract liabilities 52,775 – 52,775 Current portion of operating lease liabilities 3,152 – 3,152 Other current liabilities 1,655 196 1,851 Total current liabilities 93,343 196 93,539 Convertible senior notes, net 139,837 – 139,837 Operating lease liabilities, less current portion 37,077 – 37,077 Finance lease liabilities, less current portion 1,963 – 1,963 Total liabilities 272,220 196 272,416 Commitments and contingencies Stockholders’ equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates – – – Common stock, $0.001 par value; 150,000 shares authorized; 62,165 and 61,807 shares issued and outstanding at respective dates 62 – 62 Additional paid-in capital 608,750 – 608,750 Accumulated deficit (429,813 ) (203 ) (430,016 ) Total stockholders’ equity 178,999 (203 ) 178,796 Total liabilities and stockholders’ equity $ 451,219 $ (7 ) $ 451,212 Schedule of consolidated statement of income and comprehensive income Three Months Ended July 31, 2022 Condensed Consolidated Statement of Income and Comprehensive Income (as reported) (corrections) (as corrected) Revenues $ 36,692 $ – $ 36,692 Cost of revenues 27,575 – 27,575 Gross profit 9,117 – 9,117 Operating expenses: Selling, general and administrative 6,382 – 6,382 Total operating expenses 6,382 – 6,382 Operating income 2,735 – 2,735 Interest expense (518 ) (323 ) (841 ) Other income (expense), net 50 – 50 Net income before income taxes 2,267 (323 ) 1,944 Income tax expense 703 (120 ) 583 Net income $ 1,564 $ (203 ) $ 1,361 Comprehensive income $ 1,564 $ (203 ) $ 1,361 Net income per share: Basic $ 0.03 $ (0.01 ) $ 0.02 Diluted $ 0.02 $ – $ 0.02 Weighted average common shares outstanding: Basic 61,905 – 61,905 Diluted 63,333 – 63,333 Schedule of condensed consolidated statement of stockholders’ equity Three Months Ended July 31, 2022 Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (corrections) (as corrected) (as corrected) Balances at April 30, 2022 $ (431,377 ) $ 174,526 $ – $ (431,377 ) $ 174,526 Common stock issued under equity compensation plans – 1,012 – – 1,012 Stock-based compensation expense – 1,897 – – 1,897 Net income 1,564 1,564 (203 ) 1,361 1,361 Balances at July 31, 2022 $ (429,813 ) $ 178,999 $ (203 ) $ (430,016 ) $ 178,796 Schedule of consolidated statement of cash flows Three Months Ended July 31, 2022 Condensed Consolidated Statement of Cash Flows (as reported) (corrections) (as corrected) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 1,564 $ (203 ) $ 1,361 Adjustments to reconcile net income to net cash used in operating activities: Stock-based compensation 1,897 – 1,897 Depreciation and amortization 1,590 – 1,590 Amortization of debt issuance costs 260 – 260 Deferred income taxes 610 (48 ) 562 Loss on disposal of property and equipment 34 – 34 Changes in operating assets and liabilities: Accounts receivable, net (5,398 ) – (5,398 ) Contract assets (1,709 ) – (1,709 ) Inventory (4,292 ) – (4,292 ) Prepaid expenses and other assets (355 ) – (355 ) Accounts payable 4,242 – 4,242 Accrued compensation and benefits (3,118 ) – (3,118 ) Contract liabilities (1,023 ) – (1,023 ) Other accrued expenses and liabilities 664 196 860 Net cash used in operating activities (5,034 ) (55 ) (5,089 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (6,924 ) 55 (6,869 ) Net cash used in investing activities (6,924 ) 55 (6,869 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock under equity compensation plans 1,012 – 1,012 Principal payments on finance lease (83 ) – (83 ) Net cash provided by financing activities 929 – 929 Net decrease in cash, cash equivalents and restricted cash (11,029 ) – (11,029 ) Cash, cash equivalents and restricted cash, beginning of period 126,516 – 126,516 Cash, cash equivalents and restricted cash, end of period $ 115,487 $ – $ 115,487 Supplemental disclosures of cash flow information: Cash paid for interest $ 23 $ – $ 23 Cash paid for income taxes $ 40 $ – $ 40 Supplemental disclosures of non-cash activities: Unpaid purchases of property and equipment $ 16,674 $ – $ 16,674 Unpaid financial lease obligation $ 41 $ – $ 41

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Apr. 30, 2023
Accounting Policies [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all short-term investments readily convertible to cash, without notice or penalty, with an initial maturity of 90 days or less to be cash equivalents.
Restricted Cash	Restricted Cash Under the terms of an operating lease related to one of our facilities (Note 4), we are required to maintain a letter of credit as collateral. Accordingly, at April 30, 2023 and 2022, restricted cash of $ 0.4 million The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Schedule of restricted cash As of April 30, 2023 2022 2021 Cash and cash equivalents $ 38,542 $ 126,166 $ 169,915 Restricted cash 350 350 350 Total cash, cash equivalents and restricted cash $ 38,892 $ 126,516 $ 170,265
Revenue Recognition	Revenue Recognition We recognize revenue in accordance with the authoritative guidance of ASC 606, Revenue from Contracts with Customers Revenue recognized from services provided under our customer contracts is disaggregated into manufacturing and process development revenue streams. Manufacturing revenue Manufacturing revenue generally represents revenue from the manufacturing of customer products recognized over time utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimates for the entire cost of the performance obligation. Under a manufacturing contract, a quantity of manufacturing runs are ordered at a specified scale with prescribed delivery dates, where the product is manufactured according to the customer’s specifications and typically includes only one performance obligation. Each manufacturing run represents a distinct service that is sold separately and has stand-alone value to the customer. The products are manufactured exclusively for a specific customer and have no alternative use. The customer retains control of its product during the entire manufacturing process and can make changes to the process or specifications at its request. Under these agreements, we are entitled to consideration for progress to date that includes an element of profit margin. Process development revenue Process development revenue generally represents revenue from services associated with the custom development of a manufacturing process and analytical methods for a customer’s product. Process development revenue is recognized over time utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimates for the entire cost of the performance obligation. Under a process development contract, the customer owns the product details and process, which has no alternative use. These process development projects are customized to each customer to meet its specifications and typically includes only one performance obligation. Each process represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by our services and can make changes to its process or specifications upon request. Under these agreements, we are entitled to consideration for progress to date that includes an element of profit margin. The following table summarizes our manufacturing and process development revenue streams (in thousands): Disaggregation of revenue Fiscal Year Ended April 30, 2023 2022 2021 Manufacturing revenues $ 125,416 $ 99,282 $ 83,678 Process development revenues 23,850 20,315 12,190 Total revenues $ 149,266 $ 119,597 $ 95,868 The timing of revenue recognition, billings and cash collections results in billed accounts receivable, contract assets (unbilled receivables), and contract liabilities (customer deposits and deferred revenue). Contract assets are recorded when our right to consideration is conditioned on something other than the passage of time. Contract assets are reclassified to accounts receivable on the consolidated balance sheet when our rights become unconditional. Contract liabilities represent customer deposits and deferred revenue billed and/or received in advance of our fulfillment of performance obligations. Contract liabilities convert to revenue as we perform our obligations under the contract. During the fiscal years ended April 30, 2023 and 2022, we recognized revenue of $ 40.8 million 34 The transaction price for services provided under our customer contracts reflects our best estimates of the amount of consideration to which we are entitled in exchange for providing goods and services to our customers. For contracts with multiple performance obligations, we allocate transaction price to each performance obligation identified in a contract on a relative standalone selling price basis. We generally determine relative standalone selling prices based on the price observed in the customer contract for each distinct performance obligation. If observable standalone selling prices are not available, we may estimate the applicable standalone selling price based on the pricing of other comparable services or on a price that we believe the market is willing to pay for the applicable service. In determining the transaction price, we also considered the different sources of variable consideration including, but not limited to, discounts, credits, refunds, price concessions or other similar items. We have included in the transaction price some or all of an amount of variable consideration, utilizing the most likely method, only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The actual amount of consideration ultimately received may differ. In addition, our customer contracts generally include provisions entitling us to a cancellation or postponement fee when a customer cancels or postpones its commitments prior to our initiation of services, therefore not utilizing their reserved capacity. The determination of such cancellation and postponement fees are based on the terms stated in the related customer contract but are generally considered substantive for accounting purposes and create an enforceable right and obligation due to us when the cancellation or postponement occurs. Accordingly, we recognize such fees, subject to variable consideration, as revenue upon the cancellation or postponement date utilizing the most likely method. Management may be required to exercise judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations, estimating variable consideration, and estimating the progress towards the satisfaction of performance obligations. If actual results in the future vary from our estimates, the estimates will be adjusted, which will affect revenues in the period that such variances become known. During the fiscal year ended April 30, 2023, we recognized revenue of $ 3.0 million 14.7 million We apply the practical expedient available under ASC 606 that permits us not to disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. As of April 30, 2023, we do not have any unsatisfied performance obligations for contracts greater than one year. Costs incurred to obtain a contract are not material. These costs are generally employee sales commissions, which are expensed as incurred and included in selling, general and administrative expense in the consolidated statements of income and comprehensive income.
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable is primarily comprised of amounts owed to us for services provided under our customer contracts and are recorded at the invoiced amount net of an allowance for doubtful accounts, if necessary. We apply judgment in assessing the ultimate realization of our receivables and we estimate an allowance for doubtful accounts based on various factors, such as the aging of our receivables, historical experience, and the financial condition of our customers. Based on our analysis of our accounts receivable balance as of April 30, 2023, we determined an allowance for doubtful accounts of $ 0.5 million Based on our analysis of our accounts receivable balance as of April 30, 2022, we determined an allowance for doubtful accounts of $ 18.4 million
Concentrations of Credit Risk and Customer Base	Concentrations of Credit Risk and Customer Base Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents, accounts receivable, net and contract assets. As of April 30, 2023 and 2022, we maintain our cash balances primarily with a major commercial bank and our deposits held with the bank exceed the amount of government insurance limits provided on our deposits. We are exposed to credit risk in the event of default by the major commercial bank holding our cash balances to the extent of the cash amounts recorded on the accompanying consolidated balance sheets exceed the amount of government insurance limits provided on our deposits. Our accounts receivable from amounts billed for services provided under customer contracts are derived from a limited number of customers. Most customer contracts require up-front payments and installment payments during the service period. We perform periodic evaluations of the financial condition of our customers and generally do not require collateral, but we can terminate any contract if a material default occurs. At April 30, 2023 and 2022, approximately 76% and 84%, respectively, of our accounts receivable, net were due from our top ten customers. Our revenues are derived from a limited number of customers. Historically, these customers have not entered into long-term contracts because their need for drug supply depends on a variety of factors, including a product’s stage of development, the timing of regulatory filings and approvals, the product needs of their collaborators, if applicable, their financial resources and the market demand with respect to a commercial product. The table below identifies each of our customers that accounted for 10% or more of our total revenues during any of the fiscal years ended April 30, 2023, 2022 and 2021: Concentration of revenues Customer Geographic Location 2023 2022 2021 Halozyme Therapeutics, Inc. (1) U.S. 53 % 41 % 51 % IGM Biosciences, Inc. U.S. * 11 * Gilead Sciences, Inc. U.S. – * 16 ______________ (1) Revenues are derived from the manufacture of multiple therapeutics that our customer uses in various products and product candidates. * Represents a percentage less than 10% of our total revenues. We attribute revenue to the individual countries where the customer is headquartered. Approximately 100
Leases	Leases We account for our leases in accordance with the authoritative guidance of ASC 842, Leases Our operating leases may include options to extend the lease which are included in the lease term when it is reasonably certain that we will exercise a renewal option. Operating lease expense is recognized on a straight-line basis over the expected lease term. Our finance lease with a term greater than one year is included as an asset within property and equipment, net and a lease liability equal to the present value of the minimum lease payments is included in other current liabilities and finance lease liabilities, less current portion in our consolidated balance sheets. The present value of the finance lease payments is calculated using the implicit interest rate in the lease. Finance lease ROU assets are amortized on a straight-line basis over the expected useful life of the asset and the carrying amount of the lease liability is adjusted to reflect interest, which is recorded as interest expense. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets and lease expense for these short-term leases is recognized on a straight-line basis over the lease term. We have also elected the practical expedient to not separate lease components from non-lease components.
Inventory	Inventory Inventory consists of raw materials inventory and is valued at the lower of cost, determined by the first-in, first-out method, or net realizable value. We periodically review raw materials inventory for potential impairment and adjust inventory to its net realizable value based on the estimate of future use and reduce the carrying value of inventory as deemed necessary.
Property and Equipment	Property and Equipment Property and equipment is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the related asset, which are generally as follows: Schedule of estimated useful lives of property Description Estimated Useful Life Leasehold improvements Shorter of estimated useful life or lease term Laboratory and manufacturing equipment 5 – 15 years Computer equipment and software 3 – 5 years Furniture, fixtures and office equipment 5 – 10 years Costs for property and equipment not yet placed into service have been capitalized as construction-in-progress. These costs are primarily related to equipment and leasehold improvements associated with our manufacturing facilities, and will be depreciated in accordance with the above guidelines once placed into service. Interest costs incurred during construction of major capital projects are capitalized as construction-in-progress until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Interest capitalized as construction-in-progress for the fiscal years ended April 30, 2023 and 2022, was $ 0.8 million 0.2 million Schedule of property and equipment April 30, 2023 2022 (as restated) Leasehold improvements $ 97,514 $ 37,345 Laboratory and manufacturing equipment 35,501 30,089 Computer equipment and software 5,028 5,326 Furniture, fixtures and office equipment 1,681 843 Construction-in-progress 68,414 43,809 Total property and equipment, gross 208,138 117,412 Less: accumulated depreciation and amortization (30,368 ) (24,457 ) Total property and equipment, net $ 177,770 $ 92,955 Depreciation and amortization expense for the fiscal years ended April 30, 2023, 2022 and 2021 was $ 7.2 million 4.5 million 3.5 million
Capitalized Software Implementation Cost	Capitalized Software Implementation Cost We capitalize certain implementation costs incurred under cloud computing hosting arrangements. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within other assets on the accompanying consolidated balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.
Impairment	Impairment Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. If such events or changes in circumstances arise, we compare the carrying amount of the long-lived assets to the estimated future undiscounted cash flows expected to be generated by the long-lived assets. If the long-lived assets are determined to be impaired, any excess of the carrying value of the long-lived assets over its estimated fair value is recognized as an impairment loss. For the fiscal year ended April 30, 2023, there were indicators of impairment of the value of certain long-lived assets that resulted in an impairment loss of $ 0.1 million no
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts in the accompanying consolidated balance sheets for cash and cash equivalents, restricted cash, accounts receivable, net, accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy: · Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities. · Level 2 – Observable inputs other than quoted prices included in Level 1, such as assets or liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. · Level 3 – Unobservable inputs that are supported by little or no market activity and significant to the overall fair value measurement of the assets or liabilities; therefore requiring the company to develop its own valuation techniques and assumptions. As of April 30, 2023 and 2022, we did not have any Level 2 or Level 3 financial assets and our cash equivalents of $ 28.7 million 116.3 million
Stock-Based Compensation	Stock-Based Compensation We account for stock options, restricted stock units, performance stock units and other stock-based awards granted under our equity compensation plans in accordance with the authoritative guidance of ASC 718, Compensation – Stock Compensation
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs related to convertible senior notes are recorded as a deduction that is netted against the principal value of the debt and are amortized to interest expense using the effective interest method over the contractual term of the debt (Note 3). Debt issuance costs related to the revolving credit facility are included in prepaid expenses and other current assets in the consolidated balance sheet at April 30, 2023 and are amortized to interest expense over the contractual term of the revolving credit facility (Note 3).
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred and included in selling, general and administrative expenses in the consolidated statements of income and comprehensive income. For the fiscal years ended April 30, 2023, 2022 and 2021, advertising costs were $ 0.7 million 0.6 million 0.3 million
Income Taxes	Income Taxes We utilize the liability method of accounting for income taxes in accordance with ASC 740, Income Taxes 115 We are required to file federal and state income tax returns in various jurisdictions. The preparation of these returns requires us to interpret the applicable tax laws in effect in such jurisdictions, which could affect the amount paid by us.
Comprehensive Income	Comprehensive Income Comprehensive income is the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income is equal to our net income for all periods presented.
Accounting Standards Not Yet Adopted	Accounting Standards Not Yet Adopted In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates

Description of Company and Ba_2

Description of Company and Basis of Presentation (Tables)	12 Months Ended
	Apr. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of consolidated financial statements	Schedule of consolidated financial statements As of April 30, 2023 Consolidated Balance Sheet (as reported) (adjustments) (as restated) ASSETS Current assets: Cash and cash equivalents $ 38,542 $ – $ 38,542 Accounts receivable, net 18,298 – 18,298 Contract assets 9,609 – 9,609 Inventory 43,908 – 43,908 Prepaid expenses and other current assets 2,094 – 2,094 Total current assets 112,451 – 112,451 Property and equipment, net 177,369 401 177,770 Operating lease right-of-use assets 42,772 – 42,772 Deferred tax assets 113,639 112 113,751 Other assets 4,473 – 4,473 Restricted cash 350 – 350 Total assets $ 451,054 $ 513 $ 451,567 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 24,593 $ – $ 24,593 Accrued compensation and benefits 8,780 – 8,780 Contract liabilities 37,352 – 37,352 Convertible senior notes, net – 140,623 140,623 Current portion of operating lease liabilities 1,358 – 1,358 Other current liabilities 1,626 814 2,440 Total current liabilities 73,709 141,437 215,146 Convertible senior notes, net 140,623 (140,623 ) – Operating lease liabilities, less current portion 45,690 – 45,690 Finance lease liabilities, less current portion 1,562 – 1,562 Total liabilities 261,584 814 262,398 Commitments and contingencies – – – Stockholders’ equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates – – – Common stock, $0.001 par value; 150,000 shares authorized; 62,692 and 61,807 shares issued and outstanding at respective dates 63 – 63 Additional paid-in capital 620,224 – 620,224 Accumulated deficit (430,817 ) (301 ) (431,118 ) Total stockholders’ equity 189,470 (301 ) 189,169 Total liabilities and stockholders’ equity $ 451,054 $ 513 $ 451,567
Schedule of consolidated statement of income and comprehensive income	Schedule of consolidated statement of income and comprehensive income Year Ended April 30, 2023 Consolidated Statement of Income and Comprehensive Income (as reported) (adjustments) (as restated) Revenues $ 149,266 $ – $ 149,266 Cost of revenues 117,786 – 117,786 Gross profit 31,480 – 31,480 Operating expenses: Selling, general and administrative 27,879 – 27,879 Total operating expenses 27,879 – 27,879 Operating income 3,601 – 3,601 Interest expense (2,600 ) (413 ) (3,013 ) Other income, net 1,002 – 1,002 Net income before income taxes 2,003 (413 ) 1,590 Income tax expense 1,443 (112 ) 1,331 Net income $ 560 $ (301 ) $ 259 Comprehensive income $ 560 $ (301 ) $ 259 Net income per share: Basic $ 0.01 $ (0.01 ) $ 0.00 Diluted $ 0.01 $ (0.01 ) $ 0.00 Weighted average common shares outstanding: Basic 62,268 – 62,268 Diluted 63,782 – 63,782
Schedule of condensed consolidated statement of stockholders’ equity	Schedule of condensed consolidated statement of stockholders’ equity Year Ended April 30, 2023 Accumulated Deficit Total Stockholders’ Equity Adjustments Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at April 30, 2022 $ (431,377 ) $ 174,526 $ – $ (431,377 ) $ 174,526 Common stock issued under equity compensation plans – 3,406 – – 3,406 Stock-based compensation expense – 10,978 – – 10,978 Net income 560 560 (301 ) 259 259 Balances at April 30, 2023 $ (430,817 ) $ 189,470 $ (301 ) $ (431,118 ) $ 189,169
Schedule of consolidated statement of cash flows	Schedule of consolidated statement of cash flows Year Ended April 30, 2023 Consolidated Statement of Cash Flows (as reported) (adjustments) (as restated) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 560 $ (301 ) $ 259 Adjustments to reconcile net income to net cash used in operating activities: Stock-based compensation 10,978 – 10,978 Depreciation and amortization 7,210 – 7,210 Amortization of debt issuance costs 1,046 – 1,046 Deferred income taxes 1,443 (112 ) 1,331 Loss on disposal and/or impairment of property and equipment 139 – 139 Changes in operating assets and liabilities: Accounts receivable, net 2,249 – 2,249 Contract assets (4,240 ) – (4,240 ) Inventory (17,846 ) – (17,846 ) Prepaid expenses and other assets (61 ) – (61 ) Accounts payable 964 – 964 Accrued compensation and benefits 362 – 362 Contract liabilities (16,446 ) – (16,446 ) Other accrued expenses and liabilities 755 578 1,333 Net cash used in operating activities (12,887 ) 165 (12,722 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (77,638 ) (165 ) (77,803 ) Net cash used in investing activities (77,638 ) (165 ) (77,803 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock under equity compensation plans 3,406 – 3,406 Principal payments on finance leases (505 ) – (505 ) Net cash provided by financing activities 2,901 – 2,901 Net decrease in cash, cash equivalents and restricted cash (87,624 ) – (87,624 ) Cash, cash equivalents and restricted cash, beginning of period 126,516 – 126,516 Cash, cash equivalents and restricted cash, end of period $ 38,892 – $ 38,892 Supplemental disclosures of cash flow information: Cash paid for interest $ 1,118 $ – $ 1,118 Cash paid for income taxes $ 260 $ – $ 260 Supplemental disclosures of non-cash activities: Unpaid purchases of property and equipment $ 14,125 $ 236 $ 14,361

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Apr. 30, 2023
Accounting Policies [Abstract]
Schedule of restricted cash	Schedule of restricted cash As of April 30, 2023 2022 2021 Cash and cash equivalents $ 38,542 $ 126,166 $ 169,915 Restricted cash 350 350 350 Total cash, cash equivalents and restricted cash $ 38,892 $ 126,516 $ 170,265
Disaggregation of revenue	Disaggregation of revenue Fiscal Year Ended April 30, 2023 2022 2021 Manufacturing revenues $ 125,416 $ 99,282 $ 83,678 Process development revenues 23,850 20,315 12,190 Total revenues $ 149,266 $ 119,597 $ 95,868
Concentration of revenues	Concentration of revenues Customer Geographic Location 2023 2022 2021 Halozyme Therapeutics, Inc. (1) U.S. 53 % 41 % 51 % IGM Biosciences, Inc. U.S. * 11 * Gilead Sciences, Inc. U.S. – * 16 ______________ (1) Revenues are derived from the manufacture of multiple therapeutics that our customer uses in various products and product candidates. * Represents a percentage less than 10% of our total revenues.
Schedule of estimated useful lives of property	Schedule of estimated useful lives of property Description Estimated Useful Life Leasehold improvements Shorter of estimated useful life or lease term Laboratory and manufacturing equipment 5 – 15 years Computer equipment and software 3 – 5 years Furniture, fixtures and office equipment 5 – 10 years
Schedule of property and equipment	Schedule of property and equipment April 30, 2023 2022 (as restated) Leasehold improvements $ 97,514 $ 37,345 Laboratory and manufacturing equipment 35,501 30,089 Computer equipment and software 5,028 5,326 Furniture, fixtures and office equipment 1,681 843 Construction-in-progress 68,414 43,809 Total property and equipment, gross 208,138 117,412 Less: accumulated depreciation and amortization (30,368 ) (24,457 ) Total property and equipment, net $ 177,770 $ 92,955

Debt (as restated) (Tables)

Debt (as restated) (Tables)	12 Months Ended
	Apr. 30, 2023
Debt Disclosure [Abstract]
Schedule of net carrying amount of the debt component	Schedule of net carrying amount of the debt component April 30, 2023 April 30, 2022 Principal $ 143,750 $ 143,750 Unamortized issuance costs (3,127 ) (4,173 ) Net carrying amount $ 140,623 $ 139,577
Schedule of interest expenses	Schedule of interest expenses Fiscal Year Ended April 30, 2023 2022 2021 (as restated) Contractual interest expense $ 1,808 $ 1,603 $ 245 Amortization of issuance costs 1,046 1,030 54 Amortization of debt discount (1) – – 862 Total interest expense associated with 2026 Notes $ 2,854 $ 2,633 $ 1,161 _______________ (1) As discussed above, the adoption of ASU 2020-06 on May 1, 2021 resulted in the re-combination of the debt and equity components of the 2026 Notes into a single debt instrument. Accordingly, the unamortized debt discount balance and the net carrying amount of the equity component were derecognized.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Apr. 30, 2023
Leases
Schedule of lease costs	Schedule of lease costs Fiscal Year Ended April 30, 2023 2022 2021 Operating lease cost $ 4,386 $ 3,872 $ 3,151 Variable lease cost 1,408 944 676 Short-term lease cost 576 515 388 Finance lease costs: Amortization of right-of-use assets 216 43 82 Interest on lease liabilities 125 47 4 Total lease costs $ 6,711 $ 5,421 $ 4,301
Balance sheet classification of leases	Balance sheet classification of leases April 30, Leases Classification 2023 2022 Assets Operating Operating lease right-of-use assets $ 42,772 $ 36,806 Finance Property and equipment, net 2,529 2,728 Total leased assets $ 45,301 $ 39,534 Liabilities Current: Operating Current portion of operating lease liabilities $ 1,358 $ 2,969 Finance Other current liabilities 531 505 Non-current: Operating Operating lease liabilities, less current portion 45,690 37,886 Finance Finance lease liabilities, less current portion 1,562 2,093 Total lease liabilities $ 49,141 $ 43,453
Operating and finance leases	Operating and finance leases Weighted average remaining lease term (years): Operating leases 16.6 12.4 Finance lease 3.7 4.7 Weighted average discount rate Operating leases 6.0 3.3 Finance lease 5.3 5.3
Schedule of supplemental cash flow information related to leases	Schedule of supplemental cash flow information related to leases Fiscal Year Ended April 30, 2023 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 4,069 $ 2,376 $ 2,972 Operating cash flows from finance leases 125 47 5 Financing cash flows from finance leases 505 162 93 Non-cash transactions: Right-of-use assets obtained upon operating lease modifications and reassessments, net $ 9,267 $ 4,554 $ – Right-of-use assets obtained in exchange for operating lease obligations $ – $ 16,093 $ – Decapitalization of right-of-use assets upon impairment $ 89 $ – $ – Property and equipment obtained in exchange for finance lease obligation $ – $ 2,760 $ –
Schedule of maturities of operating lease liabilities	Schedule of maturities of operating lease liabilities Fiscal Year Ending April 30, Operating Leases Finance Lease Total 2024 $ 4,140 $ 629 $ 4,769 2025 4,060 629 4,689 2026 4,167 629 4,796 2027 4,199 419 4,618 2028 4,036 – 4,036 Thereafter 56,418 – 56,418 Total lease payments $ 77,020 $ 2,306 $ 79,326 Less: imputed interest (29,972 ) (213 ) (30,185 ) Total lease liabilities $ 47,048 $ 2,093 $ 49,141

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Apr. 30, 2023
Equity [Abstract]
Schedule of common stock reserved for future issuance	Schedule of common stock reserved for future issuance Shares Stock Incentive Plans 8,338 Employee Stock Purchase Plan 963 Conversion of Convertible Notes 6,776 Total common stock reserved for future issuance 16,077

Equity Compensation Plans (Tabl

Equity Compensation Plans (Tables)	12 Months Ended
	Apr. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of fair value assumptions for options	Schedule of fair value assumptions for options Fiscal Year Ended April 30, 2022 2021 Risk-free interest rate 0.86 0.32 Expected life (in years) 4.37 4.69 Expected volatility 68.64 81.42 Expected dividend yield – –
Schedule of stock option activity	Schedule of stock option activity Stock Options (in thousands) Grant Date Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (1) (in thousands) Outstanding at May 1, 2022 2,505 $ 6.88 Granted – – Exercised (366 ) $ 7.06 Canceled or expired (60 ) $ 9.89 Outstanding at April 30, 2023 2,079 $ 6.76 3.69 $ 23,654 Vested and expected to vest 2,079 $ 6.76 3.69 $ 23,654 Exercisable at April 30, 2023 1,595 $ 6.52 3.59 $ 18,447 ______________ (1) Aggregate intrinsic value represents the difference between the exercise price of an option and the closing market price of our common stock on April 28, 2023 (the last trading day of fiscal year 2023), which was $18.05 per share.
Schedule of RSU activity	Schedule of RSU activity Shares (in thousands) Weighted Average Grant Date Fair Value Outstanding at May 1, 2022 642 $ 14.89 Granted 780 $ 17.63 Vested (366 ) $ 15.09 Forfeited (50 ) $ 17.32 Outstanding at April 30, 2023 1,006 $ 16.83
Schedule of PSU activity	Schedule of PSU activity Shares (in thousands) Weighted Average Grant Date Fair Value Outstanding at May 1, 2022 233 $ 25.31 Granted 608 $ 18.09 Vested (161 ) $ 20.75 Forfeited (158 ) $ 20.69 Outstanding at April 30, 2023 522 $ 19.70
Schedule of ESPP Fair value assumptions	Schedule of ESPP Fair value assumptions Fiscal Year Ended April 30, 2023 2022 2021 Risk-free interest rate 3.76 0.15 0.14 Expected life (in years) 0.50 0.50 0.50 Expected volatility 68.60 59.91 75.50 Expected dividend yield – – –
Schedule of share-based compensation expense	Schedule of share-based compensation expense Fiscal Year Ended April 30, 2023 2022 2021 Cost of revenues $ 3,876 $ 2,540 $ 1,404 Selling, general and administrative expense 7,102 4,840 2,450 Total $ 10,978 $ 7,380 $ 3,854

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Apr. 30, 2023
Income Tax Disclosure [Abstract]
Schedule of provision for income taxes	Schedule of provision for income taxes 2023 2022 2021 (as restated) Federal income taxes at statutory rate $ 334 $ 2,659 $ 2,355 State income taxes, net of valuation allowance 276 605 – Expiration and adjustments of deferred tax assets – – 451 Change in federal valuation allowance – (122,703 ) 2,450 Stock-based compensation including 162M limitations 615 (1,153 ) (240 ) Research and development credits – – (4,958 ) Adjustment for federal benefit of state – 5,326 – Permanent differences 66 425 4 Other, net 40 (170 ) (62 ) Income tax expense (benefit) $ 1,331 $ (115,011 ) $ –
Schedule of deferred tax assets and deferred tax liabilities	Schedule of deferred tax assets and deferred tax liabilities 2023 2022 (as restated) Net operating losses $ 112,194 $ 99,710 Research and development credits 5,569 5,550 Stock-based compensation 2,589 2,710 Deferred revenue 2,420 5,494 Lease liabilities 12,742 11,107 Accrued liabilities 2,360 785 Accrued compensation 1,781 1,705 Total deferred tax assets 139,655 127,061 Less valuation allowance – – Total deferred tax assets, net of valuation allowance 139,655 127,061 Deferred tax liabilities: Fixed assets (14,320 ) (1,972 ) ROU assets (11,584 ) (10,007 ) Total deferred tax liabilities (25,904 ) (11,979 ) Net deferred tax assets $ 113,751 $ 115,082
Schedule of unrecognized tax positions	Schedule of unrecognized tax positions 2023 2022 Unrecognized tax positions, beginning of year $ 5,133 $ 1,600 Gross (decrease) increase – prior period tax positions (1,693 ) 3,533 Unrecognized tax positions, end of year $ 3,440 $ 5,133

Net Income Per Common Share (Ta

Net Income Per Common Share (Tables)	12 Months Ended
	Apr. 30, 2023
Net income per share attributable to common stockholders:
Schedule of earnings per share, basic and diluted	Schedule of earnings per share, basic and diluted Fiscal Year Ended April 30, 2023 2022 2021 (as restated) Numerator Net income $ 259 $ 127,672 $ 11,212 Series E preferred stock accumulated dividends – – (4,455 ) Impact of Series E preferred stock redemption – – (3,439 ) Net income attributable to common stockholders, basic $ 259 $ 127,672 $ 3,318 Add interest expense on 2026 Notes, net of tax – 1,954 – Net income attributable to common stockholders, diluted $ 259 $ 129,626 $ 3,318 Denominator Weighted average basic common shares outstanding 62,268 61,484 58,222 Effect of dilutive securities: Stock options 1,248 1,830 909 RSUs, PSUs and ESPP 266 384 295 2026 Notes – 6,776 – Weighted average dilutive common shares outstanding 63,782 70,474 59,426 Net income per share attributable to common stockholders: Basic $ 0.00 $ 2.08 $ 0.06 Diluted $ 0.00 $ 1.84 $ 0.06
Schedule of antidilutive shares	Schedule of antidilutive shares Fiscal Year Ended April 30, 2023 2022 2021 Stock options 46 43 829 RSUs, PSUs and ESPP 253 9 – 2026 Notes 6,776 – 928 Series E Preferred Stock – – 1,864 Total 7,075 52 3,621

Restatement of Previously Rep_2

Restatement of Previously Reported Fiscal 2023 Interim Financial Statements (Unaudited) (Tables)	12 Months Ended
	Apr. 30, 2023
Schedule of consolidated balance sheet	Schedule of consolidated financial statements As of April 30, 2023 Consolidated Balance Sheet (as reported) (adjustments) (as restated) ASSETS Current assets: Cash and cash equivalents $ 38,542 $ – $ 38,542 Accounts receivable, net 18,298 – 18,298 Contract assets 9,609 – 9,609 Inventory 43,908 – 43,908 Prepaid expenses and other current assets 2,094 – 2,094 Total current assets 112,451 – 112,451 Property and equipment, net 177,369 401 177,770 Operating lease right-of-use assets 42,772 – 42,772 Deferred tax assets 113,639 112 113,751 Other assets 4,473 – 4,473 Restricted cash 350 – 350 Total assets $ 451,054 $ 513 $ 451,567 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 24,593 $ – $ 24,593 Accrued compensation and benefits 8,780 – 8,780 Contract liabilities 37,352 – 37,352 Convertible senior notes, net – 140,623 140,623 Current portion of operating lease liabilities 1,358 – 1,358 Other current liabilities 1,626 814 2,440 Total current liabilities 73,709 141,437 215,146 Convertible senior notes, net 140,623 (140,623 ) – Operating lease liabilities, less current portion 45,690 – 45,690 Finance lease liabilities, less current portion 1,562 – 1,562 Total liabilities 261,584 814 262,398 Commitments and contingencies – – – Stockholders’ equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates – – – Common stock, $0.001 par value; 150,000 shares authorized; 62,692 and 61,807 shares issued and outstanding at respective dates 63 – 63 Additional paid-in capital 620,224 – 620,224 Accumulated deficit (430,817 ) (301 ) (431,118 ) Total stockholders’ equity 189,470 (301 ) 189,169 Total liabilities and stockholders’ equity $ 451,054 $ 513 $ 451,567
Schedule of consolidated statement of income and comprehensive income	Schedule of consolidated statement of income and comprehensive income Year Ended April 30, 2023 Consolidated Statement of Income and Comprehensive Income (as reported) (adjustments) (as restated) Revenues $ 149,266 $ – $ 149,266 Cost of revenues 117,786 – 117,786 Gross profit 31,480 – 31,480 Operating expenses: Selling, general and administrative 27,879 – 27,879 Total operating expenses 27,879 – 27,879 Operating income 3,601 – 3,601 Interest expense (2,600 ) (413 ) (3,013 ) Other income, net 1,002 – 1,002 Net income before income taxes 2,003 (413 ) 1,590 Income tax expense 1,443 (112 ) 1,331 Net income $ 560 $ (301 ) $ 259 Comprehensive income $ 560 $ (301 ) $ 259 Net income per share: Basic $ 0.01 $ (0.01 ) $ 0.00 Diluted $ 0.01 $ (0.01 ) $ 0.00 Weighted average common shares outstanding: Basic 62,268 – 62,268 Diluted 63,782 – 63,782
Schedule of condensed consolidated statement of stockholders’ equity	Schedule of condensed consolidated statement of stockholders’ equity Year Ended April 30, 2023 Accumulated Deficit Total Stockholders’ Equity Adjustments Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at April 30, 2022 $ (431,377 ) $ 174,526 $ – $ (431,377 ) $ 174,526 Common stock issued under equity compensation plans – 3,406 – – 3,406 Stock-based compensation expense – 10,978 – – 10,978 Net income 560 560 (301 ) 259 259 Balances at April 30, 2023 $ (430,817 ) $ 189,470 $ (301 ) $ (431,118 ) $ 189,169
Schedule of consolidated statement of cash flows	Schedule of consolidated statement of cash flows Year Ended April 30, 2023 Consolidated Statement of Cash Flows (as reported) (adjustments) (as restated) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 560 $ (301 ) $ 259 Adjustments to reconcile net income to net cash used in operating activities: Stock-based compensation 10,978 – 10,978 Depreciation and amortization 7,210 – 7,210 Amortization of debt issuance costs 1,046 – 1,046 Deferred income taxes 1,443 (112 ) 1,331 Loss on disposal and/or impairment of property and equipment 139 – 139 Changes in operating assets and liabilities: Accounts receivable, net 2,249 – 2,249 Contract assets (4,240 ) – (4,240 ) Inventory (17,846 ) – (17,846 ) Prepaid expenses and other assets (61 ) – (61 ) Accounts payable 964 – 964 Accrued compensation and benefits 362 – 362 Contract liabilities (16,446 ) – (16,446 ) Other accrued expenses and liabilities 755 578 1,333 Net cash used in operating activities (12,887 ) 165 (12,722 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (77,638 ) (165 ) (77,803 ) Net cash used in investing activities (77,638 ) (165 ) (77,803 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock under equity compensation plans 3,406 – 3,406 Principal payments on finance leases (505 ) – (505 ) Net cash provided by financing activities 2,901 – 2,901 Net decrease in cash, cash equivalents and restricted cash (87,624 ) – (87,624 ) Cash, cash equivalents and restricted cash, beginning of period 126,516 – 126,516 Cash, cash equivalents and restricted cash, end of period $ 38,892 – $ 38,892 Supplemental disclosures of cash flow information: Cash paid for interest $ 1,118 $ – $ 1,118 Cash paid for income taxes $ 260 $ – $ 260 Supplemental disclosures of non-cash activities: Unpaid purchases of property and equipment $ 14,125 $ 236 $ 14,361
January 31, 2023 [Member]
Schedule of consolidated balance sheet	Schedule of consolidated balance sheet As of January 31, 2023 Condensed Consolidated Balance Sheet (as reported) (adjustments) (as restated) ASSETS Current assets: Cash and cash equivalents $ 59,916 $ – $ 59,916 Accounts receivable, net 14,826 – 14,826 Contract assets 10,388 – 10,388 Inventory 45,102 – 45,102 Prepaid expenses and other current assets 2,111 – 2,111 Total current assets 132,343 – 132,343 Property and equipment, net 164,292 118 164,410 Operating lease right-of-use assets 34,463 – 34,463 Deferred tax assets 114,580 237 114,817 Other assets 4,402 – 4,402 Restricted cash 350 – 350 Total assets $ 450,430 $ 355 $ 450,785 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 36,392 $ – $ 36,392 Accrued compensation and benefits 8,400 – 8,400 Contract liabilities 37,750 – 37,750 Convertible senior notes, net – 140,359 140,359 Current portion of operating lease liabilities 3,024 – 3,024 Other current liabilities 1,753 630 2,383 Total current liabilities 87,319 140,989 228,308 Convertible senior notes, net 140,359 (140,359 ) – Operating lease liabilities, less current portion 35,659 – 35,659 Finance lease liabilities, less current portion 1,698 – 1,698 Total liabilities 265,035 630 265,665 Commitments and contingencies – – – Stockholders’ equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates – – – Common stock, $0.001 par value; 150,000 shares authorized; 62,523 and 61,807 shares issued and outstanding at respective dates 62 – 62 Additional paid-in capital 615,841 – 615,841 Accumulated deficit (430,508 ) (275 ) (430,783 ) Total stockholders’ equity 185,395 (275 ) 185,120 Total liabilities and stockholders’ equity $ 450,430 $ 355 $ 450,785
Schedule of consolidated statement of income and comprehensive income	Schedule of consolidated statement of income and comprehensive income Three Months Ended January 31, 2023 Condensed Consolidated Statement of Income (Loss) and Comprehensive Income (Loss) (as reported) (adjustments) (as restated) Revenues $ 38,018 $ – $ 38,018 Cost of revenues 28,193 – 28,193 Gross profit 9,825 – 9,825 Operating expenses: Selling, general and administrative 7,107 – 7,107 Total operating expenses 7,107 – 7,107 Operating income 2,718 – 2,718 Interest expense (620 ) (16 ) (636 ) Other income (expense), net 432 – 432 Net income before income taxes 2,530 (16 ) 2,514 Income tax expense 2,069 692 2,761 Net income (loss) $ 461 $ (708 ) $ (247 ) Comprehensive income (loss) $ 461 $ (708 ) $ (247 ) Net income (loss) per share: Basic $ 0.01 $ (0.01 ) $ (0.00 ) Diluted $ 0.01 $ (0.01 ) $ (0.00 ) Weighted average common shares outstanding: Basic 62,388 – 62,388 Diluted 63,726 5,438 69,164 Nine Months Ended January 31, 2023 Condensed Consolidated Statement of Income and Comprehensive Income (as reported) (adjustments) (as restated) Revenues $ 109,467 $ – $ 109,467 Cost of revenues 86,378 – 86,378 Gross profit 23,089 – 23,089 Operating expenses: Selling, general and administrative 20,320 – 20,320 Total operating expenses 20,320 – 20,320 Operating income 2,769 – 2,769 Interest expense (1,841 ) (513 ) (2,354 ) Other income (expense), net 627 – 627 Net income before income taxes 1,555 (513 ) 1,042 Income tax expense 686 (238 ) 448 Net income $ 869 $ (275 ) $ 594 Comprehensive income $ 869 $ (275 ) $ 594 Net income per share: Basic $ 0.01 $ – $ 0.01 Diluted $ 0.01 $ – $ 0.01 Weighted average common shares outstanding: Basic 62,166 – 62,166 Diluted 63,634 – 63,634
Schedule of condensed consolidated statement of stockholders’ equity	Schedule of condensed consolidated statement of stockholders’ equity Three Months Ended January 31, 2023 Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at October 31, 2022 $ (430,969 ) $ 181,195 $ 433 $ (430,536 ) $ 181,628 Common stock issued under equity compensation plans – 995 – – 995 Stock-based compensation expense – 2,744 – – 2,744 Net income (loss) 461 461 (708 ) (247 ) (247 ) Balances at January 31, 2023 $ (430,508 ) $ 185,395 $ (275 ) $ (430,783 ) $ 185,120 Nine Months Ended January 31, 2023 Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at April 30, 2022 $ (431,377 ) $ 174,526 $ – $ (431,377 ) $ 174,526 Common stock issued under equity compensation plans – 2,573 – – 2,573 Stock-based compensation expense – 7,427 – – 7,427 Net income 869 869 (275 ) 594 594 Balances at January 31, 2023 $ (430,508 ) $ 185,395 $ (275 ) $ (430,783 ) $ 185,120
Schedule of consolidated statement of cash flows	Schedule of consolidated statement of cash flows Nine Months Ended January 31, 2023 Condensed Consolidated Statement of Cash Flows (as reported) (adjustments) (as restated) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 869 $ (275 ) $ 594 Adjustments to reconcile net income to net cash used in operating activities: Stock-based compensation 7,427 – 7,427 Depreciation and amortization 5,326 – 5,326 Amortization of debt issuance costs 782 – 782 Deferred income taxes 502 (237 ) 265 Loss on disposal of property and equipment 82 – 82 Changes in operating assets and liabilities: Accounts receivable, net 5,721 – 5,721 Contract assets (5,019 ) – (5,019 ) Inventory (19,040 ) – (19,040 ) Prepaid expenses and other assets (7 ) – (7 ) Accounts payable 2,904 – 2,904 Accrued compensation and benefits (18 ) – (18 ) Contract liabilities (16,048 ) – (16,048 ) Other accrued expenses and liabilities 833 331 1,164 Net cash used in operating activities (15,686 ) (181 ) (15,867 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (52,761 ) 181 (52,580 ) Net cash used in investing activities (52,761 ) 181 (52,580 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock under equity compensation plans 2,573 – 2,573 Principal payments on finance lease (376 ) – (376 ) Net cash provided by financing activities 2,197 – 2,197 Net decrease in cash, cash equivalents and restricted cash (66,250 ) – (66,250 ) Cash, cash equivalents and restricted cash, beginning of period 126,516 – 126,516 Cash, cash equivalents and restricted cash, end of period $ 60,266 – $ 60,266 Supplemental disclosures of cash flow information: Cash paid for interest $ 224 $ 268 $ 492 Cash paid for income taxes $ 220 $ – $ 220 Supplemental disclosures of investing non-cash activities: Unpaid purchases of property and equipment $ 23,984 $ 299 $ 24,283
October 31, 2022 [Member]
Schedule of consolidated balance sheet	Schedule of consolidated balance sheet As of October 31, 2022 Condensed Consolidated Balance Sheet (as reported) (adjustments) (as restated) ASSETS Current assets: Cash and cash equivalents $ 77,292 $ – $ 77,292 Accounts receivable, net 20,580 – 20,580 Contract assets 6,528 – 6,528 Inventory 39,061 – 39,061 Prepaid expenses and other current assets 2,480 – 2,480 Total current assets 145,941 – 145,941 Property and equipment, net 139,386 (49 ) 139,337 Operating lease right-of-use assets 35,373 – 35,373 Deferred tax assets 116,647 930 117,577 Other assets 4,153 – 4,153 Restricted cash 350 – 350 Total assets $ 441,850 $ 881 $ 442,731 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 23,328 $ – $ 23,328 Accrued compensation and benefits 6,007 – 6,007 Contract liabilities 48,446 – 48,446 Convertible senior notes, net – 140,097 140,097 Current portion of operating lease liabilities 3,111 – 3,111 Other current liabilities 1,485 448 1,933 Total current liabilities 82,377 140,545 222,922 Convertible senior notes, net 140,097 (140,097 ) – Operating lease liabilities, less current portion 36,350 – 36,350 Finance lease liabilities, less current portion 1,831 – 1,831 Total liabilities 260,655 448 261,103 Commitments and contingencies – – – Stockholders’ equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates – – – Common stock, $0.001 par value; 150,000 shares authorized; 62,308 and 61,807 shares issued and outstanding at respective dates 62 – 62 Additional paid-in capital 612,102 – 612,102 Accumulated deficit (430,969 ) 433 (430,536 ) Total stockholders’ equity 181,195 433 181,628 Total liabilities and stockholders’ equity $ 441,850 $ 881 $ 442,731
Schedule of consolidated statement of income and comprehensive income	Schedule of consolidated statement of income and comprehensive income Three Months Ended October 31, 2022 Condensed Consolidated Statement of Loss and Comprehensive Loss (as reported) (adjustments) (as restated) Revenues $ 34,757 $ – $ 34,757 Cost of revenues 30,610 – 30,610 Gross profit 4,147 – 4,147 Operating expenses: Selling, general and administrative 6,831 – 6,831 Total operating expenses 6,831 – 6,831 Operating loss (2,684 ) – (2,684 ) Interest expense (703 ) (174 ) (877 ) Other income, net 145 – 145 Net loss before income taxes (3,242 ) (174 ) (3,416 ) Income tax benefit (2,086 ) (810 ) (2,896 ) Net loss $ (1,156 ) $ 636 $ (520 ) Comprehensive loss $ (1,156 ) $ 636 $ (520 ) Net loss per share: Basic $ (0.02 ) $ 0.01 $ (0.01 ) Diluted $ (0.02 ) $ 0.01 $ (0.01 ) Weighted average common shares outstanding: Basic 62,204 – 62,204 Diluted 62,204 – 62,204 Six Months Ended October 31, 2022 Condensed Consolidated Statement of Income and Comprehensive Income (as reported) (adjustments) (as restated) Revenues $ 71,449 $ – $ 71,449 Cost of revenues 58,185 – 58,185 Gross profit 13,264 – 13,264 Operating expenses: Selling, general and administrative 13,213 – 13,213 Total operating expenses 13,213 – 13,213 Operating income 51 – 51 Interest expense (1,221 ) (497 ) (1,718 ) Other income, net 195 – 195 Net loss before income taxes (975 ) (497 ) (1,472 ) Income tax benefit (1,383 ) (930 ) (2,313 ) Net income $ 408 $ 433 $ 841 Comprehensive income $ 408 $ 433 $ 841 Net income per share: Basic $ 0.01 $ – $ 0.01 Diluted $ 0.01 $ (0.01 ) $ (0.00 ) Weighted average common shares outstanding: Basic 62,054 – 62,054 Diluted 63,574 6,776 70,350
Schedule of condensed consolidated statement of stockholders’ equity	Schedule of condensed consolidated statement of stockholders’ equity Three Months Ended October 31, 2022 Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at July 31, 2022 $ (429,813 ) $ 178,999 $ (203 ) $ (430,016 ) $ 178,796 Common stock issued under equity compensation plans – 566 – – 566 Stock-based compensation expense – 2,786 – – 2,786 Net loss (1,156 ) (1,156 ) 636 (520 ) (520 ) Balances at October 31, 2022 $ (430,969 ) $ 181,195 $ 433 $ (430,536 ) $ 181,628 Six Months Ended October 31, 2022 Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (adjustments) (as restated) (as restated) Balances at April 30, 2022 $ (431,377 ) $ 174,526 $ – $ (431,377 ) $ 174,526 Common stock issued under equity compensation plans – 1,578 – – 1,578 Stock-based compensation expense – 4,683 – – 4,683 Net income 408 408 433 841 841 Balances at October 31, 2022 $ (430,969 ) $ 181,195 $ 433 $ (430,536 ) $ 181,628
Schedule of consolidated statement of cash flows	Schedule of consolidated statement of cash flows Six Months Ended October 31, 2022 Condensed Consolidated Statement of Cash Flows (as reported) (adjustments) (as restated) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 408 $ 433 $ 841 Adjustments to reconcile net income to net cash used in operating activities: Stock-based compensation 4,683 – 4,683 Depreciation and amortization 3,409 – 3,409 Amortization of debt issuance costs 520 – 520 Deferred income taxes (1,565 ) (930 ) (2,495 ) Loss on disposal of property and equipment 70 – 70 Changes in operating assets and liabilities: Accounts receivable, net (33 ) – (33 ) Contract assets (1,159 ) – (1,159 ) Inventory (12,999 ) – (12,999 ) Prepaid expenses and other assets (127 ) – (127 ) Accounts payable 5,346 – 5,346 Accrued compensation and benefits (2,411 ) – (2,411 ) Contract liabilities (5,352 ) – (5,352 ) Other accrued expenses and liabilities 439 342 781 Net cash used in operating activities (8,771 ) (155 ) (8,926 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (41,432 ) 155 (41,277 ) Net cash used in investing activities (41,432 ) 155 (41,277 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock under equity compensation plans 1,578 – 1,578 Principal payments on finance leases (249 ) – (249 ) Net cash provided by financing activities 1,329 – 1,329 Net decrease in cash, cash equivalents and restricted cash (48,874 ) – (48,874 ) Cash, cash equivalents and restricted cash, beginning of period 126,516 – 126,516 Cash, cash equivalents and restricted cash, end of period $ 77,642 – $ 77,642 Supplemental disclosures of cash flow information: Cash paid for interest $ 438 $ 312 $ 750 Cash paid for income taxes $ 220 $ – $ 220 Supplemental disclosures of non-cash activities: Unpaid purchases of property and equipment $ 8,478 $ 106 $ 8,584
July 312022 [Member]
Schedule of consolidated balance sheet	Schedule of consolidated balance sheet As of July 31, 2022 Condensed Consolidated Balance Sheet (as reported) (corrections) (as corrected) ASSETS Current assets: Cash and cash equivalents $ 115,137 $ – $ 115,137 Accounts receivable, net 25,945 – 25,945 Contract assets 7,078 – 7,078 Inventory 30,354 – 30,354 Prepaid expenses 2,121 – 2,121 Total current assets 180,635 – 180,635 Property and equipment, net 114,929 (55 ) 114,874 Operating lease right-of-use assets 36,093 – 36,093 Deferred tax assets 114,472 48 114,520 Other assets 4,740 – 4,740 Restricted cash 350 – 350 Total assets $ 451,219 $ (7 ) $ 451,212 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 30,461 $ – $ 30,461 Accrued compensation and benefits 5,300 – 5,300 Contract liabilities 52,775 – 52,775 Current portion of operating lease liabilities 3,152 – 3,152 Other current liabilities 1,655 196 1,851 Total current liabilities 93,343 196 93,539 Convertible senior notes, net 139,837 – 139,837 Operating lease liabilities, less current portion 37,077 – 37,077 Finance lease liabilities, less current portion 1,963 – 1,963 Total liabilities 272,220 196 272,416 Commitments and contingencies Stockholders’ equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates – – – Common stock, $0.001 par value; 150,000 shares authorized; 62,165 and 61,807 shares issued and outstanding at respective dates 62 – 62 Additional paid-in capital 608,750 – 608,750 Accumulated deficit (429,813 ) (203 ) (430,016 ) Total stockholders’ equity 178,999 (203 ) 178,796 Total liabilities and stockholders’ equity $ 451,219 $ (7 ) $ 451,212
Schedule of consolidated statement of income and comprehensive income	Schedule of consolidated statement of income and comprehensive income Three Months Ended July 31, 2022 Condensed Consolidated Statement of Income and Comprehensive Income (as reported) (corrections) (as corrected) Revenues $ 36,692 $ – $ 36,692 Cost of revenues 27,575 – 27,575 Gross profit 9,117 – 9,117 Operating expenses: Selling, general and administrative 6,382 – 6,382 Total operating expenses 6,382 – 6,382 Operating income 2,735 – 2,735 Interest expense (518 ) (323 ) (841 ) Other income (expense), net 50 – 50 Net income before income taxes 2,267 (323 ) 1,944 Income tax expense 703 (120 ) 583 Net income $ 1,564 $ (203 ) $ 1,361 Comprehensive income $ 1,564 $ (203 ) $ 1,361 Net income per share: Basic $ 0.03 $ (0.01 ) $ 0.02 Diluted $ 0.02 $ – $ 0.02 Weighted average common shares outstanding: Basic 61,905 – 61,905 Diluted 63,333 – 63,333
Schedule of condensed consolidated statement of stockholders’ equity	Schedule of condensed consolidated statement of stockholders’ equity Three Months Ended July 31, 2022 Accumulated Deficit Total Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity Condensed Consolidated Statement of Stockholders’ Equity (as reported) (as reported) (corrections) (as corrected) (as corrected) Balances at April 30, 2022 $ (431,377 ) $ 174,526 $ – $ (431,377 ) $ 174,526 Common stock issued under equity compensation plans – 1,012 – – 1,012 Stock-based compensation expense – 1,897 – – 1,897 Net income 1,564 1,564 (203 ) 1,361 1,361 Balances at July 31, 2022 $ (429,813 ) $ 178,999 $ (203 ) $ (430,016 ) $ 178,796
Schedule of consolidated statement of cash flows	Schedule of consolidated statement of cash flows Three Months Ended July 31, 2022 Condensed Consolidated Statement of Cash Flows (as reported) (corrections) (as corrected) CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 1,564 $ (203 ) $ 1,361 Adjustments to reconcile net income to net cash used in operating activities: Stock-based compensation 1,897 – 1,897 Depreciation and amortization 1,590 – 1,590 Amortization of debt issuance costs 260 – 260 Deferred income taxes 610 (48 ) 562 Loss on disposal of property and equipment 34 – 34 Changes in operating assets and liabilities: Accounts receivable, net (5,398 ) – (5,398 ) Contract assets (1,709 ) – (1,709 ) Inventory (4,292 ) – (4,292 ) Prepaid expenses and other assets (355 ) – (355 ) Accounts payable 4,242 – 4,242 Accrued compensation and benefits (3,118 ) – (3,118 ) Contract liabilities (1,023 ) – (1,023 ) Other accrued expenses and liabilities 664 196 860 Net cash used in operating activities (5,034 ) (55 ) (5,089 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment (6,924 ) 55 (6,869 ) Net cash used in investing activities (6,924 ) 55 (6,869 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock under equity compensation plans 1,012 – 1,012 Principal payments on finance lease (83 ) – (83 ) Net cash provided by financing activities 929 – 929 Net decrease in cash, cash equivalents and restricted cash (11,029 ) – (11,029 ) Cash, cash equivalents and restricted cash, beginning of period 126,516 – 126,516 Cash, cash equivalents and restricted cash, end of period $ 115,487 $ – $ 115,487 Supplemental disclosures of cash flow information: Cash paid for interest $ 23 $ – $ 23 Cash paid for income taxes $ 40 $ – $ 40 Supplemental disclosures of non-cash activities: Unpaid purchases of property and equipment $ 16,674 $ – $ 16,674 Unpaid financial lease obligation $ 41 $ – $ 41

Description of Company and Ba_3

Description of Company and Basis of Presentation (Details - Balance sheet) - USD ($) $ in Thousands	Apr. 30, 2023	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2020
Current assets:
Cash and cash equivalents	$ 38,542	$ 59,916	$ 77,292	$ 115,137	$ 126,166	$ 169,915
Accounts receivable, net	18,298	14,826	20,580	25,945	20,547
Contract assets	9,609	10,388	6,528	7,078	5,369
Inventory	43,908	45,102	39,061	30,354	26,062
Prepaid expenses and other current assets	2,094	2,111	2,480		1,879
Total current assets	112,451	132,343	145,941	180,635	180,023
Property and equipment, net	177,770	164,410			92,955
Operating lease right-of-use assets	42,772	34,463	35,373	36,093	36,806
Deferred tax assets	113,751	114,817	117,577	114,520	115,082
Other assets	4,473	4,402	4,153	4,740	4,627
Restricted cash	350	350	350	350	350	350
Total assets	451,567	450,785	442,731	451,212	429,843
Current liabilities:
Accounts payable	24,593	36,392	23,328	30,461	9,504
Accrued compensation and benefits	8,780	8,400	6,007	5,300	8,418
Contract liabilities	37,352	37,750	48,446	52,775	53,798
Convertible senior notes, net	140,623	140,359	140,097		0
Current portion of operating lease liabilities	1,358	3,024	3,111	3,152	2,969
Other current liabilities	2,440	2,383	1,933	1,851	1,072
Total current liabilities	215,146	228,308	222,922	93,539	75,761
Convertible senior notes, net	0	0	0	139,837
Operating lease liabilities, less current portion	45,690	35,659	36,350	37,077	37,886
Finance lease liabilities, less current portion	1,562	1,698	1,831	1,963	2,093
Total liabilities	262,398	265,665	261,103	272,416	255,317
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates	0	0	0	0	0
Common stock, $0.001 par value; 150,000 shares authorized; 62,308 and 61,807 shares issued and outstanding at respective dates	63	62	62	62	62
Additional paid-in capital	620,224	615,841	612,102	608,750	605,841
Accumulated deficit	(431,118)	(430,783)	(430,536)	(430,016)	(431,377)
Total stockholders’ equity	189,169	185,120	181,628	178,796	174,526	$ 77,736	$ 41,896
Total liabilities and stockholders’ equity	451,567	450,785	442,731	451,212	429,843
Property and equipment, net			139,337	114,874
Previously Reported [Member]
Current assets:
Cash and cash equivalents	38,542	59,916	77,292	115,137
Accounts receivable, net	18,298	14,826	20,580	25,945
Contract assets	9,609	10,388	6,528	7,078
Inventory	43,908	45,102	39,061	30,354
Prepaid expenses and other current assets	2,094	2,111	2,480
Total current assets	112,451	132,343	145,941	180,635
Property and equipment, net	177,369	164,292
Operating lease right-of-use assets	42,772	34,463	35,373	36,093
Deferred tax assets	113,639	114,580	116,647	114,472
Other assets	4,473	4,402	4,153	4,740
Restricted cash	350	350	350	350
Total assets	451,054	450,430	441,850	451,219
Current liabilities:
Accounts payable	24,593	36,392	23,328	30,461
Accrued compensation and benefits	8,780	8,400	6,007	5,300
Contract liabilities	37,352	37,750	48,446	52,775
Convertible senior notes, net	0	0	0
Current portion of operating lease liabilities	1,358	3,024	3,111	3,152
Other current liabilities	1,626	1,753	1,485	1,655
Total current liabilities	73,709	87,319	82,377	93,343
Convertible senior notes, net	140,623	140,359	140,097	139,837
Operating lease liabilities, less current portion	45,690	35,659	36,350	37,077
Finance lease liabilities, less current portion	1,562	1,698	1,831	1,963
Total liabilities	261,584	265,035	260,655	272,220
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates	0	0	0	0
Common stock, $0.001 par value; 150,000 shares authorized; 62,308 and 61,807 shares issued and outstanding at respective dates	63	62	62	62
Additional paid-in capital	620,224	615,841	612,102	608,750
Accumulated deficit	(430,817)	(430,508)	(430,969)	(429,813)
Total stockholders’ equity	189,470	185,395	181,195	178,999	174,526
Total liabilities and stockholders’ equity	451,054	450,430	441,850	451,219
Property and equipment, net			139,386	114,929
Revision of Prior Period, Adjustment [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0	0	0
Contract assets	0	0	0	0
Inventory	0	0	0	0
Prepaid expenses and other current assets	0	0	0
Total current assets	0	0	0	0
Property and equipment, net	401	118
Operating lease right-of-use assets	0	0	0	0
Deferred tax assets	112	237	930	48
Other assets	0	0	0	0
Restricted cash	0	0	0	0
Total assets	513	355	881	(7)
Current liabilities:
Accounts payable	0	0	0	0
Accrued compensation and benefits	0	0	0	0
Contract liabilities	0	0	0	0
Convertible senior notes, net	140,623	140,359	140,097
Current portion of operating lease liabilities	0	0	0	0
Other current liabilities	814	630	448	196
Total current liabilities	141,437	140,989	140,545	196
Convertible senior notes, net	(140,623)	(140,359)	(140,097)	0
Operating lease liabilities, less current portion	0	0	0	0
Finance lease liabilities, less current portion	0	0	0	0
Total liabilities	814	630	448	196
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates	0	0	0	0
Common stock, $0.001 par value; 150,000 shares authorized; 62,308 and 61,807 shares issued and outstanding at respective dates	0	0	0	0
Additional paid-in capital	0	0	0	0
Accumulated deficit	(301)	(275)	433	(203)
Total stockholders’ equity	(301)	(275)	433	(203)
Total liabilities and stockholders’ equity	$ 513	$ 355	881	(7)
Property and equipment, net			$ (49)	$ (55)

Description of Company and Ba_4

Description of Company and Basis of Presentation (Details - Statement of income and comprehensive income) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Revenues	$ 38,018	$ 34,757	$ 36,692	$ 71,449	$ 109,467	$ 149,266	$ 119,597	$ 95,868
Cost of revenues	28,193	30,610	27,575	58,185	86,378	117,786	82,949	66,561
Gross profit	9,825	4,147	9,117	13,264	23,089	31,480	36,648	29,307
Operating expenses:
Selling, general and administrative	7,107	6,831	6,382	13,213	20,320	27,879	21,226	17,064
Total operating expenses	7,107	6,831	6,382	13,213	20,320	27,879	21,226	17,064
Operating income	2,718	(2,684)	2,735	51	2,769	3,601	15,422	12,243
Interest expense						(3,013)	(2,680)	(1,164)
Other income, net	432	145	50	195	627	1,002	(81)	133
Net loss before income taxes	2,514	(3,416)	1,944	(1,472)	1,042	1,590	12,661	11,212
Income tax benefit	2,761	(2,896)	583	(2,313)	448	(1,331)	115,011	0
Net income	(247)	(520)	1,361	841	594	259	127,672	11,212
Comprehensive income	$ (247)	$ (520)	$ 1,361	$ 841	$ 594	$ 259	$ 127,672	$ 11,212
Net income per share:
Basic	$ 0	$ (0.01)	$ 0.02	$ 0.01	$ 0.01	$ 0	$ 2.08	$ 0.06
Diluted	$ 0	$ (0.01)	$ 0.02	$ 0	$ 0.01	$ 0	$ 1.84	$ 0.06
Weighted average common shares outstanding:
Basic	62,388	62,204	61,905	62,054	62,166	62,268	61,484	58,222
Diluted	69,164	62,204	63,333	70,350	63,634	63,782	70,474	59,426
Interest expense	$ (636)	$ 877	$ 841	$ (1,718)	$ (2,354)
Previously Reported [Member]
Revenues	38,018	34,757	36,692	71,449	109,467	$ 149,266
Cost of revenues	28,193	30,610	27,575	58,185	86,378	117,786
Gross profit	9,825	4,147	9,117	13,264	23,089	31,480
Operating expenses:
Selling, general and administrative	7,107	6,831	6,382	13,213	20,320	27,879
Total operating expenses	7,107	6,831	6,382	13,213	20,320	27,879
Operating income	2,718	(2,684)	2,735	51	2,769	3,601
Interest expense						(2,600)
Other income, net	432	145	50	195	627	1,002
Net loss before income taxes	2,530	(3,242)	2,267	(975)	1,555	2,003
Income tax benefit	2,069	(2,086)	703	(1,383)	686	(1,443)
Net income	461	(1,156)	1,564	408	869	560
Comprehensive income	$ 461	$ (1,156)	$ 1,564	$ 408	$ 869	$ 560
Net income per share:
Basic	$ 0.01	$ (0.02)	$ 0.03	$ 0.01	$ 0.01	$ 0.01
Diluted	$ 0.01	$ (0.02)	$ 0.02	$ 0.01	$ 0.01	$ 0.01
Weighted average common shares outstanding:
Basic	62,388	62,204	61,905	62,054	62,166	62,268
Diluted	63,726	62,204	63,333	63,574	63,634	63,782
Interest expense	$ (620)	$ 703	$ 518	$ (1,221)	$ (1,841)
Revision of Prior Period, Adjustment [Member]
Revenues	0	0	0	0	0	$ 0
Cost of revenues	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0
Operating expenses:
Selling, general and administrative	0	0	0	0	0	0
Total operating expenses	0	0	0	0	0	0
Operating income	0	0	0	0	0	0
Interest expense						(413)
Other income, net	0	0	0	0	0	0
Net loss before income taxes	(16)	(174)	(323)	(497)	(513)	(413)
Income tax benefit	692	(810)	(120)	(930)	(238)	112
Net income	(708)	636	(203)	433	(275)	(301)
Comprehensive income	$ (708)	$ 636	$ (203)	$ 433	$ (275)	$ (301)
Net income per share:
Basic	$ (0.01)	$ 0.01	$ (0.01)	$ 0		$ (0.01)
Diluted	$ (0.01)	$ 0.01		$ (0.01)		$ (0.01)
Weighted average common shares outstanding:
Basic	0	0	0	0	0	0
Diluted	5,438	0	0	6,776	0	0
Interest expense	$ (16)	$ 174	$ 323	$ (497)	$ (513)

Description of Company and Ba_5

Description of Company and Basis of Presentation (Details - Statement of stockholders' equity) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Beginning balance, value	$ 181,628	$ 178,796	$ 174,526	$ 174,526	$ 174,526	$ 174,526	$ 77,736	$ 41,896
Common stock issued under equity compensation plans	995	566	1,012	1,578	2,573	3,406	3,359	3,984
Stock-based compensation expense	2,744	2,786	1,897	4,683	7,427	10,978	7,380	3,854
Net income	(247)	(520)	1,361	841	594	259	127,672	11,212
Balances at April 30, 2023 (as restated)	185,120	181,628	178,796	181,628	185,120	189,169	174,526	77,736
Previously Reported [Member]
Beginning balance, value	181,195	178,999	174,526	174,526	174,526	174,526
Common stock issued under equity compensation plans	995	566	1,012	1,578	2,573	3,406
Stock-based compensation expense	2,744	2,786	1,897	4,683	7,427	10,978
Net income	461	(1,156)	1,564	408	869	560
Balances at April 30, 2023 (as restated)	185,395	181,195	178,999	181,195	185,395	189,470	174,526
Revision of Prior Period, Adjustment [Member]
Beginning balance, value	433	(203)
Common stock issued under equity compensation plans
Stock-based compensation expense
Net income	(708)	636	(203)	433	(275)	(301)
Balances at April 30, 2023 (as restated)	(275)	433	(203)	433	(275)	(301)
Retained Earnings [Member]
Beginning balance, value	(430,536)		(431,377)	(431,377)	(431,377)	(431,377)	(559,859)	(571,071)
Common stock issued under equity compensation plans
Stock-based compensation expense
Net income	(247)				594	259	127,672	11,212
Balances at April 30, 2023 (as restated)	(430,783)	(430,536)		(430,536)	(430,783)	(431,118)	(431,377)	$ (559,859)
Retained Earnings [Member] | Previously Reported [Member]
Beginning balance, value	(430,969)	(429,813)	(431,377)	(431,377)	(431,377)	(431,377)
Common stock issued under equity compensation plans
Stock-based compensation expense
Net income	461	(1,156)	1,564	408	869	560
Balances at April 30, 2023 (as restated)	(430,508)	(430,969)	(429,813)	(430,969)	(430,508)	(430,817)	(431,377)
Retained Earnings [Member] | As Restated [Member]
Beginning balance, value	$ (430,536)	(430,016)	(431,377)	(431,377)	$ (431,377)	$ (431,377)
Common stock issued under equity compensation plans
Stock-based compensation expense
Net income		(520)	1,361	841
Balances at April 30, 2023 (as restated)		$ (430,536)	$ (430,016)	$ (430,536)			$ (431,377)

Description of Company and Ba_6

Description of Company and Basis of Presentation (Details - Statement of cash flows) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ (247)	$ (520)	$ 1,361	$ 841	$ 594	$ 259	$ 127,672	$ 11,212
Adjustments to reconcile net income to net cash used in operating activities:
Stock-based compensation			1,897	4,683	7,427	10,978	7,380	3,854
Depreciation and amortization			1,590	3,409	5,326	7,210	4,480	3,453
Amortization of debt issuance costs			260	520	782	1,046	1,030	916
Deferred income taxes			562	(2,495)	265	1,331	(115,082)	0
Loss on disposal of property and equipment			34	70	82	139	381	0
Changes in operating assets and liabilities:
Accounts receivable, net			(5,398)	(33)	5,721	2,249	(1,705)	(10,236)
Contract assets			(1,709)	(1,159)	(5,019)	(4,240)	743	(2,812)
Inventory			(4,292)	(12,999)	(19,040)	(17,846)	(14,191)	(988)
Prepaid expenses and other assets			(355)	(127)	(7)	(61)	(4,232)	(1,260)
Accounts payable			4,242	5,346	2,904	964	(943)	(608)
Accrued compensation and benefits			(3,118)	(2,411)	(18)	362	(376)	5,775
Contract liabilities			(1,023)	(5,352)	(16,048)	(16,446)	3,029	21,649
Other accrued expenses and liabilities			860	781	1,164	1,333	1,279	227
Net cash used in operating activities			(5,089)	(8,926)	(15,867)	(12,722)	9,465	31,182
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			(6,869)	(41,277)		(77,803)
Net cash used in investing activities			(6,869)	(41,277)	(52,580)	(77,803)	(56,411)	(9,864)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under equity compensation plans			1,012	1,578	2,573	3,406	3,359	3,984
Principal payments on finance leases			(83)	(249)	(376)	(505)	(162)	(93)
Net cash provided by financing activities			929	1,329	2,197	2,901	3,197	112,335
Net decrease in cash, cash equivalents and restricted cash			(11,029)	(48,874)	(66,250)	(87,624)	(43,749)	133,653
Cash, cash equivalents and restricted cash, beginning of period	77,642	115,487	126,516	126,516	126,516	126,516	170,265	36,612
Cash, cash equivalents and restricted cash, end of period	60,266	77,642	115,487	77,642	60,266	38,892	126,516	170,265
Supplemental disclosures of cash flow information:
Cash paid for interest			23			1,118	1,670	5
Cash paid for income taxes			40	220	220	260	64	0
Supplemental disclosures of non-cash activities:
Unpaid purchases of property and equipment			16,674	8,584	24,283	14,361	1,190	3,939
Purchase of property and equipment					(52,580)	(77,803)	(56,411)	$ (9,864)
Cash paid for interest				750	492
Previously Reported [Member]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	461	(1,156)	1,564	408	869	560
Adjustments to reconcile net income to net cash used in operating activities:
Stock-based compensation			1,897	4,683	7,427	10,978
Depreciation and amortization			1,590	3,409	5,326	7,210
Amortization of debt issuance costs			260	520	782	1,046
Deferred income taxes			610	(1,565)	502	1,443
Loss on disposal of property and equipment			34	70	82	139
Changes in operating assets and liabilities:
Accounts receivable, net			(5,398)	(33)	5,721	2,249
Contract assets			(1,709)	(1,159)	(5,019)	(4,240)
Inventory			(4,292)	(12,999)	(19,040)	(17,846)
Prepaid expenses and other assets			(355)	(127)	(7)	(61)
Accounts payable			4,242	5,346	2,904	964
Accrued compensation and benefits			(3,118)	(2,411)	(18)	362
Contract liabilities			(1,023)	(5,352)	(16,048)	(16,446)
Other accrued expenses and liabilities			664	439	833	755
Net cash used in operating activities			(5,034)	(8,771)	(15,686)	(12,887)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			(6,924)	(41,432)		(77,638)
Net cash used in investing activities			(6,924)	(41,432)	(52,761)	(77,638)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under equity compensation plans			1,012	1,578	2,573	3,406
Principal payments on finance leases			(83)	(249)	(376)	(505)
Net cash provided by financing activities			929	1,329	2,197	2,901
Net decrease in cash, cash equivalents and restricted cash			(11,029)	(48,874)	(66,250)	(87,624)
Cash, cash equivalents and restricted cash, beginning of period	77,642	115,487	126,516	126,516	126,516	126,516
Cash, cash equivalents and restricted cash, end of period	60,266	77,642	115,487	77,642	60,266	38,892	126,516
Supplemental disclosures of cash flow information:
Cash paid for interest			23			1,118
Cash paid for income taxes			40	220	220	260
Supplemental disclosures of non-cash activities:
Unpaid purchases of property and equipment			16,674	8,478	23,984	14,125
Purchase of property and equipment					(52,761)
Cash paid for interest				438	224
Revision of Prior Period, Adjustment [Member]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	(708)	636	(203)	433	(275)	(301)
Adjustments to reconcile net income to net cash used in operating activities:
Stock-based compensation			0	0	0	0
Depreciation and amortization			0	0	0	0
Amortization of debt issuance costs			0	0	0	0
Deferred income taxes			(48)	(930)	(237)	(112)
Loss on disposal of property and equipment			0	0	0	0
Changes in operating assets and liabilities:
Accounts receivable, net			0	0	0	0
Contract assets			0	0	0	0
Inventory			0	0	0	0
Prepaid expenses and other assets			0	0	0	0
Accounts payable			0	0	0	0
Accrued compensation and benefits			0	0	0	0
Contract liabilities			0	0	0	0
Other accrued expenses and liabilities			196	342	331	578
Net cash used in operating activities			(55)	(155)	(181)	165
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			55	155		(165)
Net cash used in investing activities			55	155	181	(165)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under equity compensation plans			0	0	0	0
Principal payments on finance leases			0	0	0	0
Net cash provided by financing activities			0	0	0	0
Net decrease in cash, cash equivalents and restricted cash			0	0	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0	0	0	0	0
Cash, cash equivalents and restricted cash, end of period	$ 0	$ 0	0	0	0	0	$ 0
Supplemental disclosures of cash flow information:
Cash paid for interest			0			0
Cash paid for income taxes			0	0	0	0
Supplemental disclosures of non-cash activities:
Unpaid purchases of property and equipment			$ 0	106	299	$ 236
Purchase of property and equipment					181
Cash paid for interest				$ 312	$ 268

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details - Cash) - USD ($) $ in Thousands	Apr. 30, 2023	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 38,542	$ 59,916	$ 77,292	$ 115,137	$ 126,166	$ 169,915
Restricted cash	350	350	350	350	350	350
Total cash, cash equivalents and restricted cash	$ 38,892	$ 60,266	$ 77,642	$ 115,487	$ 126,516	$ 170,265	$ 36,612

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details - Revenue) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Product Information [Line Items]
Revenues	$ 38,018	$ 34,757	$ 36,692	$ 71,449	$ 109,467	$ 149,266	$ 119,597	$ 95,868
Manufacturing Revenue [Member]
Product Information [Line Items]
Revenues						125,416	99,282	83,678
Process Development Revenue [Member]
Product Information [Line Items]
Revenues						$ 23,850	$ 20,315	$ 12,190

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details - Percentage breakdown) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Halozyme Therapeutics [Member]
Product Information [Line Items]
Customer revenue as a percentage of revenue	53%	41%	51%
I G M Biosciences [Member]
Product Information [Line Items]
Customer revenue as a percentage of revenue		11%
Gilead Sciences [Member]
Product Information [Line Items]
Customer revenue as a percentage of revenue	0%		16%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details - Useful life)	12 Months Ended
	Apr. 30, 2023
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property and equipment	Shorter of estimated useful life or lease term
Other Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property and equipment	5 – 15 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property and equipment	3 – 5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property and equipment	5 – 10 years

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details - Property and Equipment) - USD ($) $ in Thousands	Apr. 30, 2023	Jan. 31, 2023	Apr. 30, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 208,138		$ 117,412
Less: Accumulated depreciation and amortization	(30,368)		(24,457)
Total property and equipment, net	177,770	$ 164,410	92,955
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	97,514		37,345
Manufactured Product, Other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	35,501		30,089
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,028		5,326
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,681		843
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 68,414		$ 43,809

Summary of Significant Accoun_9

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Product Information [Line Items]
Restricted cash	$ 400,000	$ 400,000
Revenue recognized for which the contract liability was recorded in the prior year	40,800,000	34,000,000
Change in revenue due to change in estimate	3,000,000	14,700,000
Allowance for doubtful accounts	500,000	18,400,000
Capitalized Interest Costs	800,000	200,000
Depreciation and amortization	7,200,000	4,500,000	$ 3,500,000
Impairment of long-lived assets	100,000
Impairment of long-lived assets		0
Cash equivalents	28,700,000	116,300,000
Advertising Expense	700,000	$ 600,000	$ 300,000
Deferred tax assets	$ 115,000,000
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer [Member] | UNITED STATES
Product Information [Line Items]
Concentration risk percentage	100%	100%

Debt (Details - Debt component)

Debt (Details - Debt component) - Convertible Debt Carrying Amount [Member] - USD ($) $ in Thousands	Apr. 30, 2023	Apr. 30, 2022
Offsetting Assets [Line Items]
Principal	$ 143,750	$ 143,750
Unamortized issuance costs	(3,127)	(4,173)
Net carrying amount	$ 140,623	$ 139,577

Debt (Details - Interest expens

Debt (Details - Interest expense) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
		Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Debt Instrument [Line Items]
Amortization of debt discount		$ 260	$ 520	$ 782	$ 1,046	$ 1,030	$ 916
Convertible Notes [Member]
Debt Instrument [Line Items]
Contractual interest expense					1,808	1,603	245
Amortization of issuance costs					1,046	1,030	54
Amortization of debt discount	[1]				0	0	862
Total interest expense associated with 2026 Notes					$ 2,854	$ 2,633	$ 1,161
[1]As discussed above, the adoption of ASU 2020-06 on May 1, 2021 resulted in the re-combination of the debt and equity components of the 2026 Notes into a single debt instrument. Accordingly, the unamortized debt discount balance and the net carrying amount of the equity component were derecognized.

Debt (as restated) (Details Nar

Debt (as restated) (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Mar. 14, 2023	Mar. 31, 2021	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Debt Instrument [Line Items]
Proceeds from Convertible Debt			$ 0	$ 0	$ 138,464,000
Revolving Credit Facility [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Revolving credit facility, description	(1) a term Secured Overnight Financing Rate (“SOFR”) rate for a specified interest period plus a SOFR adjustment (equal to 0.10%) plus a margin of 1.60% or (2) base rate plus a margin of 0.60% at our option.
Line of Credit Facility, Commitment Fee Percentage	0.25%
Revolving Credit Facility [Member] | Credit Agreement [Member]
Debt Instrument [Line Items]
Revolving credit facility, description	The Credit Agreement provides for a revolving credit facility (the “Revolving Credit Facility”) in an amount equal to the lesser of (i) $50 million, and (ii) a borrowing base calculated as the sum of (a) 80% of the value of certain of our eligible accounts receivable, plus (b) up to 100% of the value of eligible cash collateral. The Revolving Credit Facility will mature on October 25, 2024 and is secured by substantially all of our assets.
Line of credit	$ 15,000,000		0
Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt face amount		$ 143,800,000
Proceeds from Convertible Debt		138,500,000
Debt issuance costs		$ 5,300,000
Interest rate		1.25%
Maturity date		Mar. 15, 2026
Convertible Senior Notes [Member] | Debt Component [Member]
Debt Instrument [Line Items]
Debt face amount		$ 99,700,000
Debt issuance costs		$ 3,700,000
Effective discount rate		8.78%
Convertible Senior Notes [Member] | Equity Component [Member]
Debt Instrument [Line Items]
Debt face amount		$ 44,100,000
Debt issuance costs		$ 1,600,000
Convertible Notes [Member]
Debt Instrument [Line Items]
Fair value of the Convertible Notes			$ 157,300,000	$ 167,100,000
Trade price per share			$ 100	$ 100

Leases (Details - Components of

Leases (Details - Components of lease) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Leases
Operating lease cost	$ 4,386	$ 3,872	$ 3,151
Variable lease cost	1,408	944	676
Short-term lease cost	576	515	388
Finance lease costs:
Amortization of right-of-use assets	216	43	82
Interest on lease liabilities	125	47	4
Total lease costs	$ 6,711	$ 5,421	$ 4,301

Leases (Details - Operating lea

Leases (Details - Operating leases assets and liabilities) - USD ($) $ in Thousands	Apr. 30, 2023	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Apr. 30, 2022
Leases
Operating lease right-of-use assets	$ 42,772	$ 34,463	$ 35,373	$ 36,093	$ 36,806
Finance Lease - Property and equipment, net	2,529				2,728
Total leased assets	45,301				39,534
Current portion of operating lease liabilities	1,358	3,024	3,111	3,152	2,969
Finance lease - other current liabilities	531				505
Operating lease liabilities, less current portion	45,690	$ 35,659	$ 36,350	$ 37,077	37,886
Finance lease liabilities, less current portion	1,562				2,093
Total lease liabilities	$ 49,141				$ 43,453

Leases (Details - Operating and

Leases (Details - Operating and finance leases)	Apr. 30, 2023	Apr. 30, 2022
Leases
Weighted average lease term, Operating leases	16 years 7 months 6 days	12 years 4 months 24 days
Weighted average lease term, finance lease	3 years 8 months 12 days	4 years 8 months 12 days
Weighted average discount rate, operating leases	6%	3.30%
Weighted average discount rate, finance lease	5.30%	5.30%

Lease - (Details - Supplemental

Lease - (Details - Supplemental cash flow information) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 4,069	$ 2,376	$ 2,972
Operating cash flows from finance leases	125	47	5
Financing cash flows from finance leases	505	162	93
Non-cash transactions:
Right-of-use assets obtained upon operating lease modifications and reassessments, net	9,267	4,554	0
Right-of-use assets obtained in exchange for operating lease obligations	0	16,093	0
Decapitalization of right-of-use assets upon impairment	89	0	0
Property and equipment obtained in exchange for finance lease obligation	$ 0	$ 2,760	$ 0

Leases (Details - Maturities of

Leases (Details - Maturities of Operating Lease Liabilities) $ in Thousands	Apr. 30, 2023 USD ($)
2024	$ 4,769
2025	4,689
2026	4,796
2027	4,618
2028	4,036
Thereafter	56,418
Total lease payments	79,326
Less: imputed interest	(30,185)
Total lease liabilities	49,141
Finance Lease [Member]
2024	629
2025	629
2026	629
2027	419
2028	0
Thereafter	0
Total lease payments	2,306
Less: imputed interest	(213)
Total financing lease liabilities	2,093
Operating Lease [Member]
2024	4,140
2025	4,060
2026	4,167
2027	4,199
2028	4,036
Thereafter	56,418
Total lease payments	77,020
Less: imputed interest	(29,972)
Total operating lease liabilities	$ 47,048

Stockholders' Equity (Details)

Stockholders' Equity (Details) shares in Thousands	Apr. 30, 2023 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for future issuance	16,077
Conversion Of Convertible Notes [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for future issuance	6,776
Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for future issuance	8,338
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock reserved for future issuance	963

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Apr. 30, 2021	Jan. 31, 2021	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021	Apr. 21, 2021
Class of Stock [Line Items]
Stock converted, shares issued
Dividends paid					$ 4,455,000
Proceeds from sale of common stock			$ 0	$ 0	32,141,000
Payment of stock issuance costs					$ 2,359,000
Common Stock [Member]
Class of Stock [Line Items]
Stock converted, shares converted					34,000
Stock converted, shares issued
Dividends paid
Stock issued new, shares					3,833,000
Public offering share price		$ 9
Number of shares sold		500,000
Underwritten public offering of common stock			$ 0	0
Common stock shares issued			62,691,885
Common stock shares outstanding			62,691,885
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Stock converted, shares converted	28,168
Conversion price	$ 21				$ 21
Redemption price			$ 25			$ 25
Redemption value				3,400,000
Liquidation preference price per share			2.625
Accrued and unpaid dividends per share			$ 0.08021
Dividends paid			$ 0	$ 0	$ 4,500,000
Common Stock [Member]
Class of Stock [Line Items]
Stock converted, shares issued	33,514
Common Stock [Member] | Public Offering [Member]
Class of Stock [Line Items]
Stock issued new, shares		3,833,335
Proceeds from sale of common stock			34,500,000
Payment of stock issuance costs			$ 2,400,000

Equity Compensation Plans (Deta

Equity Compensation Plans (Details - Fair value assumptions for options) - Equity Option [Member]	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	0.86%	0.32%
Expected life (in years)	4 years 4 months 13 days	4 years 8 months 8 days
Expected volatility	68.64%	81.42%
Expected dividend yield	0%	0%

Equity Compensation Plans (De_2

Equity Compensation Plans (Details - Option activity) - Equity Option [Member] $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Apr. 30, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options Outstanding, Beginning | shares	2,505
Weighted Average Exercise Price Outstanding, Beginning | $ / shares	$ 6.88
Number of Options Granted | shares	0
Weighted Average Exercise Price Granted | $ / shares	$ 0
Number of Options Exercised | shares	(366)
Weighted Average Exercise Price Exercised | $ / shares	$ 7.06
Number of Options Cancelled or Expired | shares	(60)
Weighted Average Exercise Price Canceled | $ / shares	$ 9.89
Number of Options Outstanding, Ending | shares	2,079
Weighted Average Exercise Price Outstanding, Ending | $ / shares	$ 6.76
Weighted Average Remaining Contractual Life (in years) Outstanding	3 years 8 months 8 days
Aggregate Intrinsic Value Outstanding | $	$ 23,654	[1]
Exercisable and expected to vest | shares	2,079
Weighted Average Exercise Price, Exercisable and expected to vest | $ / shares	$ 6.76
Weighted Average Remaining Contractual Life (in years) Vested and expected to vest	3 years 8 months 8 days
Aggregate Intrinsic Value vested and expected to vest | $	$ 23,654	[1]
Exercisable at period end | shares	1,595
Weighted Average Exercise Price Exercisable, at period end | $ / shares	$ 6.52
Weighted Average Remaining Contractual Life (in years) Exercisable, at period end	3 years 7 months 2 days
Aggregate Intrinsic Value Exercisable at period end | $	$ 18,447	[1]
[1]Aggregate intrinsic value represents the difference between the exercise price of an option and the closing market price of our common stock on April 28, 2023 (the last trading day of fiscal year 2023), which was $18.05 per share.

Equity Compensation Plans (De_3

Equity Compensation Plans (Details - RSU Activity) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, beginning balance	642
Weighted average exercise price outstanding, beginning	$ 14.89
Granted	780
Granted, weighted average grant date fair value	$ 17.63	$ 25.20	$ 7.29
Vested	(366)
Vested, weighted average grant date fair value	$ 15.09
Forfeited	(50)
Forfeited, weighted average grant date fair value	$ 17.32
Outstanding, ending balance	1,006	642
Weighted average exercise price outstanding, ending	$ 16.83	$ 14.89

Equity Compensation Plans (De_4

Equity Compensation Plans (Details - PSU Activity) - Performance Stock Units [Member] - $ / shares shares in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, beginning balance	233
Weighted average exercise price outstanding, beginning	$ 25.31
Granted	608
Granted, weighted average grant date fair value	$ 18.09	$ 25.36	$ 0
Vested	(161)
Vested, weighted average grant date fair value	$ 20.75
Forfeited	(158)
Forfeited, weighted average grant date fair value	$ 20.69
Outstanding, ending balance	522	233
Weighted average exercise price outstanding, ending	$ 19.70	$ 25.31

Equity Compensation Plans (De_5

Equity Compensation Plans (Details - ESPP Fair value assumptions) - Employee Stock Purchase Plan [Member]	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.76%	0.15%	0.14%
Expected life (in years)	6 months	6 months	6 months
Expected volatility	68.60%	59.91%	75.50%
Expected dividend yield	0%	0%	0%

Equity Compensation Plans (De_6

Equity Compensation Plans (Details - Share based compensation) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation	$ 1,897	$ 4,683	$ 7,427	$ 10,978	$ 7,380	$ 3,854
Cost of Sales [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation				3,876	2,540	1,404
Selling General And Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation				$ 7,102	$ 4,840	$ 2,450

Equity Compensation Plans (De_7

Equity Compensation Plans (Details Narrative) - USD ($)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021	Oct. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance	16,077,000
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross	0
Proceeds from exercise of stock options	$ 2,600,000	$ 2,700,000	$ 3,600,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value of options granted	$ 0	$ 13.09	$ 4.74
Aggregate intrinsic value of stock options exercised	$ 3,500,000	$ 8,100,000	$ 3,900,000
Unrecognized compensation cost weighted average vesting period	11 months 26 days
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost weighted average vesting period	2 years 6 months 10 days
Weighted average grant date fair value, other than options	$ 17.63	$ 25.20	$ 7.29
Fair value of RSUs vested	$ 6,300,000	$ 5,500,000	$ 700,000
Unrecognized compensation cost	$ 15,400,000
Performance Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost weighted average vesting period	1 year 4 months 20 days
Weighted average grant date fair value, other than options	$ 18.09	$ 25.36	$ 0
Fair value of RSUs vested	$ 3,300,000	$ 2,100,000	$ 0
Unrecognized compensation cost	$ 10,300,000
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average grant date fair value, other than options	$ 4.93	$ 8.62	$ 3.17
Stock issued during period, ESPP	68,646	44,364	72,409
ESPP weighted average purchase price	$ 12.22	$ 14.50	$ 5.84
Plan 2018 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance				3,400,000
Stock Incentive Plans [Member] | Plan 2018 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance	8,337,807
Stock Incentive Plans [Member] | Options And Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance	3,926,550
Stock Incentive Plans [Member] | Future Grants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance	4,411,257

Income Taxes (Details - Provisi

Income Taxes (Details - Provision for Income taxes) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Income Tax Disclosure [Abstract]
Federal income taxes at statutory rate						$ 334	$ 2,659	$ 2,355
State income taxes, net of valuation allowance						276	605	0
Expiration and adjustments of deferred tax assets						0	0	451
Change in federal valuation allowance						0	(122,703)	2,450
Stock-based compensation including 162M limitations						615	(1,153)	(240)
Research and development credits						0	0	(4,958)
Adjustment for federal benefit of state						0	5,326	0
Permanent differences						66	425	4
Other, net						40	(170)	(62)
Income tax expense (benefit)	$ (2,761)	$ 2,896	$ (583)	$ 2,313	$ (448)	$ 1,331	$ (115,011)	$ 0

Income Taxes (Details - Deferre

Income Taxes (Details - Deferred income taxes) - USD ($) $ in Thousands	Apr. 30, 2023	Apr. 30, 2022
Income Tax Disclosure [Abstract]
Net operating losses	$ 112,194	$ 99,710
Research and development credits	5,569	5,550
Stock-based compensation	2,589	2,710
Deferred revenue	2,420	5,494
Lease liabilities	12,742	11,107
Accrued liabilities	2,360	785
Accrued compensation	1,781	1,705
Total deferred tax assets	139,655	127,061
Less valuation allowance	0	0
Total deferred tax assets, net of valuation allowance	139,655	127,061
Deferred tax liabilities:
Fixed assets	(14,320)	(1,972)
ROU assets	(11,584)	(10,007)
Total deferred tax liabilities	(25,904)	(11,979)
Net deferred tax assets	$ 113,751	$ 115,082

Income Taxes (Details - Unrecog

Income Taxes (Details - Unrecognized tax positions) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Income Tax Disclosure [Abstract]
Unrecognized tax positions, beginning of year	$ 5,133	$ 1,600
Gross (decrease) increase – prior period tax positions	(1,693)	3,533
Unrecognized tax positions, end of year	$ 3,440	$ 5,133

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Operating Loss Carryforwards [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 0
Valuation adjustments		$ 11,300,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forward	442,400,000
Research and development credit carry forwards	5,800,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forward	294,700,000
Research and development credit carry forwards	1,500,000
Other State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forward	$ 900,000

Net Income Per Common Share (De

Net Income Per Common Share (Details - Reconciliation of per share) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Numerator
Net income	$ (247)	$ (520)	$ 1,361	$ 841	$ 594	$ 259	$ 127,672	$ 11,212
Series E preferred stock accumulated dividends						0	0	(4,455)
Impact of Series E preferred stock redemption						0	0	(3,439)
Net income attributable to common stockholders, basic						259	127,672	3,318
Add interest expense on 2026 Notes, net of tax						0	1,954	0
Net income attributable to common stockholders, diluted						$ 259	$ 129,626	$ 3,318
Denominator
Weighted average basic common shares outstanding	62,388	62,204	61,905	62,054	62,166	62,268	61,484	58,222
Effect of dilutive securities:
Stock options						1,248	1,830	909
RSUs, PSUs and ESPP						266	384	295
2026 Notes						0	6,776	0
Weighted average dilutive common shares outstanding	69,164	62,204	63,333	70,350	63,634	63,782	70,474	59,426
Net income per share attributable to common stockholders:
Basic	$ 0	$ (0.01)	$ 0.02	$ 0.01	$ 0.01	$ 0	$ 2.08	$ 0.06
Diluted	$ 0	$ (0.01)	$ 0.02	$ 0	$ 0.01	$ 0	$ 1.84	$ 0.06

Net Income Per Common Share (_2

Net Income Per Common Share (Details - Antidilutive shares) - shares shares in Thousands	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of shares on diluted shares outstanding	7,075	52	3,621
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of shares on diluted shares outstanding	46	43	829
RSUs, PSUs, and ESPP [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of shares on diluted shares outstanding	253	9	0
2026 Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of shares on diluted shares outstanding	6,776	0	928
Series E Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of shares on diluted shares outstanding	0	0	1,864

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative) - USD ($)	12 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Retirement Benefits [Abstract]
Company matching contributions to 401(k) plan	$ 900,000	$ 600,000	$ 500,000

Schedule of consolidated balanc

Schedule of consolidated balance sheet (Details) - USD ($) $ in Thousands	Apr. 30, 2023	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2020
Current assets:
Cash and cash equivalents	$ 38,542	$ 59,916	$ 77,292	$ 115,137	$ 126,166	$ 169,915
Accounts receivable, net	18,298	14,826	20,580	25,945	20,547
Contract assets	9,609	10,388	6,528	7,078	5,369
Inventory	43,908	45,102	39,061	30,354	26,062
Prepaid expenses				2,121
Total current assets	112,451	132,343	145,941	180,635	180,023
Property and equipment, net			139,337	114,874
Operating lease right-of-use assets	42,772	34,463	35,373	36,093	36,806
Deferred tax assets	113,751	114,817	117,577	114,520	115,082
Other assets	4,473	4,402	4,153	4,740	4,627
Restricted cash	350	350	350	350	350	350
Total assets	451,567	450,785	442,731	451,212	429,843
Current liabilities:
Accounts payable	24,593	36,392	23,328	30,461	9,504
Accrued compensation and benefits	8,780	8,400	6,007	5,300	8,418
Contract liabilities	37,352	37,750	48,446	52,775	53,798
Current portion of operating lease liabilities	1,358	3,024	3,111	3,152	2,969
Other current liabilities	2,440	2,383	1,933	1,851	1,072
Total current liabilities	215,146	228,308	222,922	93,539	75,761
Convertible senior notes, net	0	0	0	139,837
Operating lease liabilities, less current portion	45,690	35,659	36,350	37,077	37,886
Finance lease liabilities, less current portion	1,562	1,698	1,831	1,963	2,093
Total liabilities	262,398	265,665	261,103	272,416	255,317
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates	0	0	0	0	0
Common stock, $0.001 par value; 150,000 shares authorized; 62,165 and 61,807 shares issued and outstanding at respective dates	63	62	62	62	62
Additional paid-in capital	620,224	615,841	612,102	608,750	605,841
Accumulated deficit	(431,118)	(430,783)	(430,536)	(430,016)	(431,377)
Total stockholders’ equity	189,169	185,120	181,628	178,796	174,526	$ 77,736	$ 41,896
Total liabilities and stockholders’ equity	451,567	450,785	442,731	451,212	429,843
Previously Reported [Member]
Current assets:
Cash and cash equivalents	38,542	59,916	77,292	115,137
Accounts receivable, net	18,298	14,826	20,580	25,945
Contract assets	9,609	10,388	6,528	7,078
Inventory	43,908	45,102	39,061	30,354
Prepaid expenses				2,121
Total current assets	112,451	132,343	145,941	180,635
Property and equipment, net			139,386	114,929
Operating lease right-of-use assets	42,772	34,463	35,373	36,093
Deferred tax assets	113,639	114,580	116,647	114,472
Other assets	4,473	4,402	4,153	4,740
Restricted cash	350	350	350	350
Total assets	451,054	450,430	441,850	451,219
Current liabilities:
Accounts payable	24,593	36,392	23,328	30,461
Accrued compensation and benefits	8,780	8,400	6,007	5,300
Contract liabilities	37,352	37,750	48,446	52,775
Current portion of operating lease liabilities	1,358	3,024	3,111	3,152
Other current liabilities	1,626	1,753	1,485	1,655
Total current liabilities	73,709	87,319	82,377	93,343
Convertible senior notes, net	140,623	140,359	140,097	139,837
Operating lease liabilities, less current portion	45,690	35,659	36,350	37,077
Finance lease liabilities, less current portion	1,562	1,698	1,831	1,963
Total liabilities	261,584	265,035	260,655	272,220
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates	0	0	0	0
Common stock, $0.001 par value; 150,000 shares authorized; 62,165 and 61,807 shares issued and outstanding at respective dates	63	62	62	62
Additional paid-in capital	620,224	615,841	612,102	608,750
Accumulated deficit	(430,817)	(430,508)	(430,969)	(429,813)
Total stockholders’ equity	189,470	185,395	181,195	178,999	174,526
Total liabilities and stockholders’ equity	451,054	450,430	441,850	451,219
Revision of Prior Period, Adjustment [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0	0	0
Contract assets	0	0	0	0
Inventory	0	0	0	0
Prepaid expenses				0
Total current assets	0	0	0	0
Property and equipment, net			(49)	(55)
Operating lease right-of-use assets	0	0	0	0
Deferred tax assets	112	237	930	48
Other assets	0	0	0	0
Restricted cash	0	0	0	0
Total assets	513	355	881	(7)
Current liabilities:
Accounts payable	0	0	0	0
Accrued compensation and benefits	0	0	0	0
Contract liabilities	0	0	0	0
Current portion of operating lease liabilities	0	0	0	0
Other current liabilities	814	630	448	196
Total current liabilities	141,437	140,989	140,545	196
Convertible senior notes, net	(140,623)	(140,359)	(140,097)	0
Operating lease liabilities, less current portion	0	0	0	0
Finance lease liabilities, less current portion	0	0	0	0
Total liabilities	814	630	448	196
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates	0	0	0	0
Common stock, $0.001 par value; 150,000 shares authorized; 62,165 and 61,807 shares issued and outstanding at respective dates	0	0	0	0
Additional paid-in capital	0	0	0	0
Accumulated deficit	(301)	(275)	433	(203)
Total stockholders’ equity	(301)	(275)	433	(203)
Total liabilities and stockholders’ equity	$ 513	$ 355	$ 881	$ (7)

Schedule of consolidated statem

Schedule of consolidated statement of income and comprehensive income (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Revenues	$ 38,018	$ 34,757	$ 36,692	$ 71,449	$ 109,467	$ 149,266	$ 119,597	$ 95,868
Cost of revenues	28,193	30,610	27,575	58,185	86,378	117,786	82,949	66,561
Gross profit	9,825	4,147	9,117	13,264	23,089	31,480	36,648	29,307
Operating expenses:
Selling, general and administrative	7,107	6,831	6,382	13,213	20,320	27,879	21,226	17,064
Total operating expenses	7,107	6,831	6,382	13,213	20,320	27,879	21,226	17,064
Operating income	2,718	(2,684)	2,735	51	2,769	3,601	15,422	12,243
Interest expense	(636)	877	841	(1,718)	(2,354)
Other income (expense), net	432	145	50	195	627	1,002	(81)	133
Net income before income taxes	2,514	(3,416)	1,944	(1,472)	1,042	1,590	12,661	11,212
Income tax expense	2,761	(2,896)	583	(2,313)	448	(1,331)	115,011	0
Net income	(247)	(520)	1,361	841	594	259	127,672	11,212
Comprehensive income	$ (247)	$ (520)	$ 1,361	$ 841	$ 594	$ 259	$ 127,672	$ 11,212
Net income per share:
Basic	$ 0	$ (0.01)	$ 0.02	$ 0.01	$ 0.01	$ 0	$ 2.08	$ 0.06
Diluted	$ 0	$ (0.01)	$ 0.02	$ 0	$ 0.01	$ 0	$ 1.84	$ 0.06
Weighted average common shares outstanding:
Basic	62,388	62,204	61,905	62,054	62,166	62,268	61,484	58,222
Diluted	69,164	62,204	63,333	70,350	63,634	63,782	70,474	59,426
Previously Reported [Member]
Revenues	$ 38,018	$ 34,757	$ 36,692	$ 71,449	$ 109,467	$ 149,266
Cost of revenues	28,193	30,610	27,575	58,185	86,378	117,786
Gross profit	9,825	4,147	9,117	13,264	23,089	31,480
Operating expenses:
Selling, general and administrative	7,107	6,831	6,382	13,213	20,320	27,879
Total operating expenses	7,107	6,831	6,382	13,213	20,320	27,879
Operating income	2,718	(2,684)	2,735	51	2,769	3,601
Interest expense	(620)	703	518	(1,221)	(1,841)
Other income (expense), net	432	145	50	195	627	1,002
Net income before income taxes	2,530	(3,242)	2,267	(975)	1,555	2,003
Income tax expense	2,069	(2,086)	703	(1,383)	686	(1,443)
Net income	461	(1,156)	1,564	408	869	560
Comprehensive income	$ 461	$ (1,156)	$ 1,564	$ 408	$ 869	$ 560
Net income per share:
Basic	$ 0.01	$ (0.02)	$ 0.03	$ 0.01	$ 0.01	$ 0.01
Diluted	$ 0.01	$ (0.02)	$ 0.02	$ 0.01	$ 0.01	$ 0.01
Weighted average common shares outstanding:
Basic	62,388	62,204	61,905	62,054	62,166	62,268
Diluted	63,726	62,204	63,333	63,574	63,634	63,782
Revision of Prior Period, Adjustment [Member]
Revenues	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Cost of revenues	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0
Operating expenses:
Selling, general and administrative	0	0	0	0	0	0
Total operating expenses	0	0	0	0	0	0
Operating income	0	0	0	0	0	0
Interest expense	(16)	174	323	(497)	(513)
Other income (expense), net	0	0	0	0	0	0
Net income before income taxes	(16)	(174)	(323)	(497)	(513)	(413)
Income tax expense	692	(810)	(120)	(930)	(238)	112
Net income	(708)	636	(203)	433	(275)	(301)
Comprehensive income	$ (708)	$ 636	$ (203)	$ 433	$ (275)	$ (301)
Net income per share:
Basic	$ (0.01)	$ 0.01	$ (0.01)	$ 0		$ (0.01)
Diluted	$ (0.01)	$ 0.01		$ (0.01)		$ (0.01)
Weighted average common shares outstanding:
Basic	0	0	0	0	0	0
Diluted	5,438	0	0	6,776	0	0

Schedule of condensed consolida

Schedule of condensed consolidated statement of stockholders’ equity (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	$ 181,628	$ 178,796	$ 174,526	$ 174,526	$ 174,526	$ 174,526	$ 77,736	$ 41,896
Common stock issued under equity compensation plans	995	566	1,012	1,578	2,573	3,406	3,359	3,984
Stock-based compensation expense	2,744	2,786	1,897	4,683	7,427	10,978	7,380	3,854
Net income	(247)	(520)	1,361	841	594	259	127,672	11,212
Balances at April 30, 2023 (as restated)	185,120	181,628	178,796	181,628	185,120	189,169	174,526	77,736
Previously Reported [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	181,195	178,999	174,526	174,526	174,526	174,526
Common stock issued under equity compensation plans	995	566	1,012	1,578	2,573	3,406
Stock-based compensation expense	2,744	2,786	1,897	4,683	7,427	10,978
Net income	461	(1,156)	1,564	408	869	560
Balances at April 30, 2023 (as restated)	185,395	181,195	178,999	181,195	185,395	189,470	174,526
Revision of Prior Period, Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	433	(203)
Common stock issued under equity compensation plans
Stock-based compensation expense
Net income	(708)	636	(203)	433	(275)	(301)
Balances at April 30, 2023 (as restated)	(275)	433	(203)	433	(275)	(301)
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	(430,536)		(431,377)	(431,377)	(431,377)	(431,377)	(559,859)	(571,071)
Common stock issued under equity compensation plans
Stock-based compensation expense
Net income	(247)				594	259	127,672	11,212
Balances at April 30, 2023 (as restated)	(430,783)	(430,536)		(430,536)	(430,783)	(431,118)	(431,377)	$ (559,859)
Retained Earnings [Member] | Previously Reported [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	(430,969)	(429,813)	(431,377)	(431,377)	(431,377)	(431,377)
Common stock issued under equity compensation plans
Stock-based compensation expense
Net income	461	(1,156)	1,564	408	869	560
Balances at April 30, 2023 (as restated)	(430,508)	(430,969)	(429,813)	(430,969)	(430,508)	(430,817)	(431,377)
Retained Earnings [Member] | As Restated [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, value	$ (430,536)	(430,016)	(431,377)	(431,377)	$ (431,377)	$ (431,377)
Common stock issued under equity compensation plans
Stock-based compensation expense
Net income		(520)	1,361	841
Balances at April 30, 2023 (as restated)		$ (430,536)	$ (430,016)	$ (430,536)			$ (431,377)

Schedule of consolidated stat_2

Schedule of consolidated statement of cash flows (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2023	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2021
Net income	$ (247)	$ (520)	$ 1,361	$ 841	$ 594	$ 259	$ 127,672	$ 11,212
Adjustments to reconcile net income to net cash used in operating activities:
Stock-based compensation			1,897	4,683	7,427	10,978	7,380	3,854
Depreciation and amortization			1,590	3,409	5,326	7,210	4,480	3,453
Amortization of debt issuance costs			260	520	782	1,046	1,030	916
Deferred income taxes			562	(2,495)	265	1,331	(115,082)	0
Loss on disposal of property and equipment			34	70	82	139	381	0
Changes in operating assets and liabilities:
Accounts receivable, net			(5,398)	(33)	5,721	2,249	(1,705)	(10,236)
Contract assets			(1,709)	(1,159)	(5,019)	(4,240)	743	(2,812)
Inventory			(4,292)	(12,999)	(19,040)	(17,846)	(14,191)	(988)
Prepaid expenses and other assets			(355)	(127)	(7)	(61)	(4,232)	(1,260)
Accounts payable			4,242	5,346	2,904	964	(943)	(608)
Accrued compensation and benefits			(3,118)	(2,411)	(18)	362	(376)	5,775
Contract liabilities			(1,023)	(5,352)	(16,048)	(16,446)	3,029	21,649
Other accrued expenses and liabilities			860	781	1,164	1,333	1,279	227
Net cash used in operating activities			(5,089)	(8,926)	(15,867)	(12,722)	9,465	31,182
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			(6,869)	(41,277)		(77,803)
Net cash used in investing activities			(6,869)	(41,277)	(52,580)	(77,803)	(56,411)	(9,864)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under equity compensation plans			1,012	1,578	2,573	3,406	3,359	3,984
Principal payments on finance lease			(83)	(249)	(376)	(505)	(162)	(93)
Net cash provided by financing activities			929	1,329	2,197	2,901	3,197	112,335
Net decrease in cash, cash equivalents and restricted cash			(11,029)	(48,874)	(66,250)	(87,624)	(43,749)	133,653
Cash, cash equivalents and restricted cash, beginning of period	77,642	115,487	126,516	126,516	126,516	126,516	170,265	36,612
Cash, cash equivalents and restricted cash, end of period	60,266	77,642	115,487	77,642	60,266	38,892	126,516	170,265
Supplemental disclosures of cash flow information:
Cash paid for interest			23			1,118	1,670	5
Cash paid for income taxes			40	220	220	260	64	0
Supplemental disclosures of non-cash activities:
Unpaid purchases of property and equipment			16,674	8,584	24,283	14,361	1,190	$ 3,939
Unpaid financial lease obligation			41
Previously Reported [Member]
Net income	461	(1,156)	1,564	408	869	560
Adjustments to reconcile net income to net cash used in operating activities:
Stock-based compensation			1,897	4,683	7,427	10,978
Depreciation and amortization			1,590	3,409	5,326	7,210
Amortization of debt issuance costs			260	520	782	1,046
Deferred income taxes			610	(1,565)	502	1,443
Loss on disposal of property and equipment			34	70	82	139
Changes in operating assets and liabilities:
Accounts receivable, net			(5,398)	(33)	5,721	2,249
Contract assets			(1,709)	(1,159)	(5,019)	(4,240)
Inventory			(4,292)	(12,999)	(19,040)	(17,846)
Prepaid expenses and other assets			(355)	(127)	(7)	(61)
Accounts payable			4,242	5,346	2,904	964
Accrued compensation and benefits			(3,118)	(2,411)	(18)	362
Contract liabilities			(1,023)	(5,352)	(16,048)	(16,446)
Other accrued expenses and liabilities			664	439	833	755
Net cash used in operating activities			(5,034)	(8,771)	(15,686)	(12,887)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			(6,924)	(41,432)		(77,638)
Net cash used in investing activities			(6,924)	(41,432)	(52,761)	(77,638)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under equity compensation plans			1,012	1,578	2,573	3,406
Principal payments on finance lease			(83)	(249)	(376)	(505)
Net cash provided by financing activities			929	1,329	2,197	2,901
Net decrease in cash, cash equivalents and restricted cash			(11,029)	(48,874)	(66,250)	(87,624)
Cash, cash equivalents and restricted cash, beginning of period	77,642	115,487	126,516	126,516	126,516	126,516
Cash, cash equivalents and restricted cash, end of period	60,266	77,642	115,487	77,642	60,266	38,892	126,516
Supplemental disclosures of cash flow information:
Cash paid for interest			23			1,118
Cash paid for income taxes			40	220	220	260
Supplemental disclosures of non-cash activities:
Unpaid purchases of property and equipment			16,674	8,478	23,984	14,125
Unpaid financial lease obligation			41
Revision of Prior Period, Adjustment [Member]
Net income	(708)	636	(203)	433	(275)	(301)
Adjustments to reconcile net income to net cash used in operating activities:
Stock-based compensation			0	0	0	0
Depreciation and amortization			0	0	0	0
Amortization of debt issuance costs			0	0	0	0
Deferred income taxes			(48)	(930)	(237)	(112)
Loss on disposal of property and equipment			0	0	0	0
Changes in operating assets and liabilities:
Accounts receivable, net			0	0	0	0
Contract assets			0	0	0	0
Inventory			0	0	0	0
Prepaid expenses and other assets			0	0	0	0
Accounts payable			0	0	0	0
Accrued compensation and benefits			0	0	0	0
Contract liabilities			0	0	0	0
Other accrued expenses and liabilities			196	342	331	578
Net cash used in operating activities			(55)	(155)	(181)	165
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			55	155		(165)
Net cash used in investing activities			55	155	181	(165)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under equity compensation plans			0	0	0	0
Principal payments on finance lease			0	0	0	0
Net cash provided by financing activities			0	0	0	0
Net decrease in cash, cash equivalents and restricted cash			0	0	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0	0	0	0	0
Cash, cash equivalents and restricted cash, end of period	$ 0	$ 0	0	0	0	0	$ 0
Supplemental disclosures of cash flow information:
Cash paid for interest			0			0
Cash paid for income taxes			0	0	0	0
Supplemental disclosures of non-cash activities:
Unpaid purchases of property and equipment			0	$ 106	$ 299	$ 236
Unpaid financial lease obligation